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This September issue of the Hong Kong Medical Diary
on Intensive Care represents the very first time the
Medical Diary has incorporated Intensive Care into the
list of medical topics to be shared with Diary readers.
The breadth of mind of the Diary Editors for
entertaining non-traditional medical subjects such as
Intensive Care and the boldness in committing one
whole issue to this subject are much to be congratulated
on for making this issue possible. Much gratitude goes
to the current and former Editors-in-Chief, Drs Chun-on
Mok and Walter King, for their kind encouragement
and support. Much gratitude also goes to the esteemed
authors of this issue, who, based on their vast
experience in managing the critically ill in the intensive
care unit (ICU), have together produced this very
handsome issue on Intensive Care.
Indeed the timing for the birth of this issue on Intensive
Care is just right. For a few decades after the initial
development of negative pressure ventilators (or so-
called iron lung) to support patients with respiratory
failure during the polio epidemic, the ICU had
remained a rather humble shapeless place, usually
serving as a post-operative recovery area, or as a pooled
nondescript repository for nursing ill patients requiring
various vital organ monitoring and support. Over the
past two-plus decades, the explosion in our knowledge
and understanding of the pathophysiology of the
critically ill, along with the vast technological advances
and increasing practice of evidence-based medicine, has
enabled the modern-day ICU to provide much more
meticulous and well-contemplated ICU care targeting
not only at saving lives but also at minimising
iatrogenesis. In this issue, we are proud to present
updates on acute renal support (by Dr. W. W. Yan), on
acute liver support (by Dr. Alex Chiu and Prof S. T.
Fan), on acute cardiac support (by Drs T. F. Tse and
Elaine Chau), on infectious disease emergencies
commonly seen in the ICU (by Drs. Vincent Cheng and
Samson Wong), on optimising sedation and analgesia
(by Dr. Judith Shen), and on respiratory support (by Dr.
Donald Yu and myself). This issue thus provides a
bird's eye view of the fast expanding global literature
and experience in Intensive Care.
This issue inevitably suffers some important omissions
because of limited space. Sepsis, a common ICU entity,
is not discussed here. For an evidence-based update on
sepsis, our readers are encouraged to look up the
website www.survivingsepsis.org recently established
jointly by the European Society of Intensive Care
Medicine, the International Sepsis Forum and the U.S.-
based Society of Critical Care Medicine. The annual
edition of The Yearbook of Intensive Care and
Emergency Medicine edited by J.-L. Vincent, Professor
and Head of a leading Intensive Care Department in
Europe is another must-read source for those who
would like to sample the amazing progress made in
Intensive Care over the years.
To match up to the artistic photography of the past
issues was a challenging task for me as an issue editor
on Intensive Care, as the prototype image of Intensive
Care can be frightening and intimidating: a patient
lying helplessly in bed with tubes and lines and
machines of various sizes and shapes hovering at the
bedside. Fortunately, Professor Richard Yu has kindly
graced our cover with the beauty of a snowy winter.
Many paradoxical emotions indeed come to mind when
one considers the ICU, such as hope/despair or
aggressive intervention/end of life. Nonetheless, the
beauty of the ICU lies in the fact that this is the place
where the sanctity of life is stretched to its farthest
limits, where timely appropriate therapeutic
interventions and organ support do matter, and where
life tragedies and miracles can be seen together. That is
the challenge of Intensive Care, and that is why
Intensive Care can be a passion for someone like myself
since my earlier days as the Director of the ICU at
Queen Mary Hospital.
This issue probably breaks the Medical Diary's record in
two other ways. Firstly, mirroring the Intensive Care
multi-disciplinary practice, our authorship comprises of
experts from many specialties. On board our authorship
team are physicians, an anaesthetist and a surgeon;
there are specialists in Cardiology, Critical Care
Medicine/Intensive Care Medicine, Hepatobiliary
Surgery, Clinical Microbiology & Infection, and
Respiratory Medicine. Mirroring the important bedside
collaboration in the ICU, our multi-disciplinary team of
authors have joined hands in the delivery of this issue
to you. Secondly, the Life Style article contributed by
Dr Gloria Pei would likely be a first in depicting the
power of a mother's love for her little one, a truly heart-
warming story.
Lastly, may I wish the Hong Kong Medical Diary every
success and our readers good health and happiness!
Editorial
Dr. Jane CK CHAN
Dr. Jane CK CHAN
Specialist in Respiratory Medicine
MD (U of Chicago), FRCPE, FHKCP, FHKAM (Medicine), PDipID (HK)
Dip American Board of Internal Medicine (Pulmonary & Critical Care Medicine)
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The Cover Shot
Prof. Richard YH YU
Early winter when the first snow fell
after X'mas in Erabandai in
Fukoshima, the image captured the
serenity and tranquility of nature
and its purity.
This photo impressionism is shared
with Dr. Leo KK Wong who is my
mentor and teacher.
MD(HK), PhD(Lond), FRCP,
Hon FRACP, Hon FHKCP,
Hon FPSHK
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Case Presentation
Patient 1. A young woman with rheumatoid
arthritis and acute respiratory failure
Background
A 33 year-old obese Chinese female, nonsmoker, with
longstanding history of rheumatoid arthritis (RA) since
childhood sequentially requiring systemic steroids,
penicillamine, oral gold, plaquenil, and 4 years earlier,
leflunomide (Arava ), was admitted directly to the ICU
for acute onset of high fever and oxygenation failure.
There had been a prodrome of fever, nonproductive
cough, shortness of breath, vomiting and diarrhoea for
a few days prior to admission. Her chest examination
revealed diffuse crepitations throughout both lungs.
Investigations
Her chest x-ray on admission showed bilateral diffuse
consolidative changes (Figure 1A). Her white cell count
was 1.72 109/L with total neutrophil count of 1.31 109/L
and lymphocyte of 0.25 109/L. The platelet count was 107
109/L. Her CRP, procalcitonin and renal function tests
were all normal. Her liver function tests were normal
except for a SGOT of 109 U/l. The ESR was 35 mm/h. A
subsequent chest CT showed extensive ground glass
consolidation in both lungs sparing only the dorsal and
apical regions consistent with acute pneumonitis (Figure
1B). The working diagnosis was fulminant community-
acquired pneumonia versus leflunomide-induced
interstitial pneumonitis. Leflunomide was promptly
discontinued. Cholestyramine was given to accelerate the
clearance of leflunomide.
Workup for Infection
She was pan-cultured on admission for high fever and
was promptly started on broad-spectrum antibiotics
including a beta-lactam, a macrolide, and anti-PCP and
anti-fungal therapy based on microbiology consultation.
She developed an episode of hypotension on Day 3, for
which stress dose steroids and intravenous
immunoglobulin were added for possible fulminant
sepsis. One dose of G-CSF was given on Day 4 for
persistent leukopenia, followed by good sustained
recovery of her white cell count in the ensuing days. The
lymphopenia persisted till Day 11. All microbiologic
workup turned out to be negative: sputum and blood
cultures, sputum for acid fast bacilli smear and PCR,
urinary antigen for Legionella and Streptococcus,
serologic titres for mycoplasma, nasopharyngeal
aspirate for influenza A and B, and serum CMV pp65.
All her immune markers were also negative.
Stormy Course in Respiratory Support
The patient required BIPAP support on Day 1
immediately upon ICU admission because of poor
oxygenation. A FIO2 of 50% on BIPAP could achieve an
oxygen saturation (SpO2) of 80-85% only. Over the
following week, her oxygenation remained very
Dr. Donald YC YU
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Figure 1A. Chest radiograph of Patient 1 on admission.
Figure 1B. Chest CT of Patient 1 on Day 8
Medical Bulletin
6
VOL.14 NO.9 SEPTEMBER 2009
marginal with SpO2 achievable above 90% at FIO2 of
?70%. Mild exertion or coughing would precipitate
marked oxygen desaturation down to 70s%. On Day 11,
as the patient's oxygenation deteriorated despite being
on BIPAP, with SpO2 barely above 90% on FIO2 80%,
the patient was intubated and tracheostomy was
performed. Ventilatory support showed a PEEP level of
15 cm together with a FIO2 of about 60% to achieve a
SpO2 of 90-91%. On Day 18, the patient was
commenced on bi-level ventilation for her fulminant
ARDS with severe oxygenation failure.
Empiric Corticosteroids
The patient's fever peaked on Day 2 but gradually came
down (possibly from stress dose steroids) over the next
few days and henceforth remained afebrile. On Day 9, in
view of the totally negative microbiologic workup, multi-
system presentation, leukopenia, lymphopenia, and the
diffuse pneumonitis, the diagnosis of leflunomide-
induced ARDS was felt to be likely. Pulse steroids in the
form of daily methylprednisolone 500 mg for 2 days was
given for the worsening respiratory failure and fulminant
ARDS, followed by pharmacologic doses of steroids with
gradual tapering over the next few weeks.
Inhaled Nitric Oxide
On Day 22, a repeat CT scan of the chest showed
worsening ground glass consolidation with reticular
shadows consistent with evolving pneumonitis. On Day
23, in view of the patient's worsening oxygenation
failure requiring FIO2 of 85%, inhaled nitric oxide (iNO)
was initiated to enhance gas exchange and for fear of
oxygen toxicity. iNO at 5 parts per million (ppm) was
administered via the InoVent. Within 12 hours of iNO
administration, the patient demonstrated pleasing
response with improvement in the SpO2 thus enabling
tapering down of FIO2. By Day 25, the patient's FIO2
came down to as low as 50-55%. iNO was brought
down gradually to 1 ppm and eventually off after a
total course of 6 days. FIO2 requirements remained
stable off iNO. On Day 34, the FIO2 requirements were
35-40% only. On Day 38, a repeat CT chest showed
partial resolution of the alveolar process and lessening
of the interstitial reticular markings.
The Road to Recovery
Her clinical course was otherwise only complicated by
Klebsiella-related ventilator-associated pneumonia
which responded to prolonged course of antibiotics. On
Day 40, the patient was switched from IV steroids to
oral prednisolone at 60 mg qd. By Day 45 she was able
to sustain spontaneous breathing most of the day. By
Day 55, the patient was completely off the ventilator,
and was soon discharged from the ICU. The patient
finally went home after a hospital stay of 3 months.
Final Diagnosis
Leflunomide-induced ARDS
Patient 2. An elderly woman with acute
respiratory failure following VATS lung biopsy
Background
A 78 year-old Chinese female, nonsmoker, with history
of hypertension and paroxysmal atrial fibrillation on
warfarin and amiodarone (Cordarone ) 100 mg bd, was
electively admitted to the hospital for wedge lung
biopsy under video-assisted thoracoscopy. There had
been a history of insidious onset of exertional dyspnoea
and recent chest x-ray and CT finding of bibasilar
subpleural infiltrates more on the left than right, with
some suggestion of honeycomb lung in the left base
(Figure 2A and 2B). Pre-operative myocardial perfusion
scan was normal, and so were her chest examination
and resting oximetry reading. VATS wedge biopsy of
the left lower lobe was performed on Day 2. Intra-
operatively, pleural fibrosis and lung nodularity were
noted on palpation. Histology of the resected lung
showed interstitial fibrosis with chronic inflammatory
infiltrate consistent with usual interstitial pneumonitis.
All stains for micro-organisms were negative.
Fulminant ARDS Postoperatively
One day following wedge lung resection (Day 3), the
patient developed low grade fever, for which antibiotics
were empirically started. On Day 4, she was noted to
have oxygen desaturation which rapidly progressed to
require BIPAP support at FIO2 of 65%. Auscultation
revealed a few bi-basilar crepitations. Chest x-ray
showed interval development of extensive airspace
consolidation in both lungs, most prominent at both
Figure 2A: Chest radiograph
of Patient 2 nine days before
admission
Figure 2C. Chest radiograph
of Patient 2 two days
following VATS lung biopsy
Figure 2B: Chest CT of Patient 2 five days before admssion
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ventilation and prolonged ICU stay. Mortality rates
remain high at 35-60%2. Management strategies for
ARDS have focused on combating the inciting insult,
ventilatory optimisation and at times cautious use of
steroids.
Drug-induced ARDS
Drug-induced lung diseases can manifest in various
clinico-pathological entities as shown in Table 1, based
on the cellular mechanism of lung injury as well as the
tempo of disease presentation, ranging from slowly
progressive pneumonitis/fibrosis to acute respiratory
failure arising from either diffuse alveolar damage
(DAD), non-cardiogenic pulmonary oedema or alveolar
haemorrhage4,5. The aetiologic link to a certain drug can
be difficult, and is usually based on a history of drug
exposure, histological evidence of lung damage, and
exclusion of other causes of lung injury, especially the
exclusion of active infection. In the milder cases,
radiographic findings of subtle ground glass opacities
and mild fibrosis can be elusive on conventional chest x-
ray and may only be seen on CT scanning5.
Despite our clinical impression to the contrary,
noncardiogenic pulmonary oedema, and to lesser extent,
ARDS, are common clinical manifestations of drug-
induced lung diseases6. The former can be mild and self-
limited, with rapid recovery following the use of oxygen
and diuretic therapy, and discontinuation of the culprit
drug. However, the more severe form, usually
presenting as fulminant ARDS, as resulting from Ara-C,
nitrofurantoin, or amiodarone, can be life-threatening
and may require ventilatory support and administration
of steroids6. Drug-induced ARDS is by and large a
diagnosis by exclusion; every effort has to be made to
exclude other important causes of ARDS, including
sepsis, fulminant pneumonia and aspiration.
Leflunomide-induced ARDS
Leflunomide (Arava ) is a disease-modifying anti-
rheumatic drug for the treatment of rheumatoid arthritis
(RA). The drug had been considered relatively safe for
quite a few years since its launch in the U.S. and E.U. in
the late 1990s, with common adverse events being
nausea, diarrhoea, headache, deranged liver enzymes,
rash, alopecia, respiratory infections and hypertension7.
However, within a few months after its release in Japan
in September 2003, 48 cases of interstitial lung disease
(ILD) were found among 4395 patients registered for
use in Japan, including 16 fatal cases, giving rise to an
incidence of 1.1%, and a fatality of 30%8. A stormy
course of acute respiratory failure from leflunomide
leading to fatality was described despite the use of high
dose steroids9, 10. Pathological findings at autopsy were
that of DAD9. DAD manifested as widespread patchy
ground glass opacities0 and/or consolidation also
appeared to be the predominant presenting finding
radiographically11.
There does appear to be a difference in the susceptibility
to leflunomide-induced lung toxicity between different
ethnic/geographic groups. Subsequent to the Japanese
findings, Canadian investigators conducted a
retrospective population-based case control
epidemiologic study reviewing more than 60,000
Canadian patients with RA on leflunomide between 1998
and 2003 and found a much lower rate of leflunomide-
lower zones. (Figure 2C) In view of the rapidly
deteriorating condition and likely non-infectious
pneumonitis, the patient was given pulse steroids in the
form of methylprednisolone 500 mg qd for 3 days from
Day 4 through Day 6 followed by prednisolone 50 mg
qd beginning on Day 7. Diuretics were also given for
possible fluid overload. From Day 7 through Day 9, the
patient was put on spontaneous breathing with oxygen
at 8 L+30%, achieving rather marginal O2 saturation of
90-94%. On Day 10, the patient appeared rather
fatigued and tachypnoeic with a respiratory rate of 40,
and required resumption of BIPAP. On Day 11, she was
transferred to the ICU for intubation and invasive
ventilation using PEEP levels of 10 cm H2O and FIO2 of
85%. However, her oxygenation failure remained
profound requiring bi-level ventilation and FIO2 up to
100%. A bronchoalveolar lavage did not reveal any
infectious aetiology for her oxygenation failure. Serum
immune markers were normal. The working diagnosis
was fulminant ARDS secondary to acute and chronic
lung injury from amiodarone. Amiodarone was
discontinued.
Empiric Treatment of Amiodarone-induced
ARDS
High dose steroids were continued. Oxygen radical
scavenger therapy was started using vitamin C, vitamin
E, pentoxylline, and N-acetylcysteine. One dose of anti-
tumour necrosis factor-alpha antibody was also given
for possible cytokine storm associated with the acute
lung injury. By Day 13, FIO2 requirement came down to
75%-85% at a PEEP level of 10 maintaining a SpO2 of
91%, by Day 15 FIO2 down to 55% with a SpO2 of 92%,
and Day 16 FIO2 down to 45% with a SpO2 of 91-92%,
consistent with encouraging clinical response.
However, she continued to demonstrate heightened
respiratory drive with persistent tachypnoea up to 40
and marked use of accessory muscles despite full
ventilatory support and generous doses of sedation.
Her ICU course was further complicated by rather
difficult-to-control atrial fibrillation, subcutaneous
emphysema, right pneumothorax, steroid-induced
diabetes, and critical illness polyneuropathy. The
patient was eventually off the ventilator on Day 30,
discharged from ICU on Day 34, and discharged home
on Day 78.
Final Diagnosis
Amiodarone-induced ARDS
Discussion
Definition of ARDS
The acute respiratory distress syndrome (ARDS), first
described in 19671, is characterised by diffuse
inflammation of the lung's alveolar-capillary membrane
in response to various pulmonary and extra-pulmonary
insults2 such as aspiration, pneumonia, sepsis, trauma,
or pancreatitis. The 1994 American-European
consensus3 on the definition of ARDS is acute onset of
Patients with ARDS invariably require mechanical
Hypoxaemia, with a PaO2/FIO2 ratio of 200 mmHg or
less,
Bilateral infiltrates on a frontal chest radiograph, and
Pulmonary artery wedge pressure < 18 mmHg or no
clinical evidence of left atrial hypertension.
(1)
(2)
(3)
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inflammatory response similar to inhalation of organic
dust15, and (2) direct drug-induced phospholipidosis17,
arising from a direct toxic effect of the drug, and
characterised by the histopathological findings of
"foamy" changes in the alveolar macrophages15. The
role of free radicals in the pathogenesis of amiodarone
toxicity was further implicated in in vitro and in vivo
models of amiodarone lung15, 18.
However, beginning in the mid-to-late 1980s, it became
increasingly apparent that the mechanism of lung injury
may differ between chronic amiodarone lung disease
and acute amiodarone-mediated lung injury. In the
former, risk groups have been identified as those who
are elderly with pre-existing lung condition on doses of
> 400 mg per day17. In the latter, which usually presents
as an acute and rapidly deteriorating, and at times fatal,
illness, the risk factors revolve around concomitant
injury rendering the lung liable to amiodarone's acute
toxic damage. These injuries include angiography19,
cardiothoracic surgery20, and lung surgery21,22 with the
most common intraoperative denominator being high
inspired oxygen concentrations23,24. Patients with
preexisting amiodarone lung were found to be at high
risk of developing ARDS after cardiothoracic
operations20. Patients without surgery but ventilated in
the ICU have also been found to be at risk of
development amiodarone-induced ARDS25.
Management of amiodarone-induced ARDS is largely
supportive. Steroids have been used empirically. In our
patient, given the severe ARDS requiring high
concentrations of oxygen to support the patient's
oxygenation, empiric use of anti-oxidant therapy was
given to minimise further oxygen toxicity. The empiric
use of anti-TNF alpha was to combat the likely cytokine
storm arising from activation of the alveolar
macrophages.
Pharmacotherapy for ARDS
Research efforts devoted to identifying the magic
bullet for combating ARDS have largely been
unproductive. In the Cochrane review of 33
randomised clinical trials involving over 3000 patients,
no pharmacotherapy was found to show convincing
improvement in survival in patients with ARDS. Use
of early high-dose steroids in ARDS was deemed not
justifiable26. The use of corticosteroids in late-phase
ARDS remains controversial. An earlier, much quoted,
small trial of 24 patients showed improved survival
when given moderate dose steroids at day 7 or more
after the onset of ARDS, during the so-called
fibroproliferative phase of ARDS27. A recent multi-
centre trial of 180 patients however showed higher
mortality when given corticosteroids at 14 days or
more after the onset of ARDS28. Two recent meta-
analyses also arrived at conflicting conclusions: the
Australian researchers concluded that the use of low-
dose corticosteroids was associated with improved
mortality and morbidity outcomes29, while the U.K.
researchers concluded that despite a suggestion of
reduced mortality and increased ventilator-free days
with steroids after the onset of ARDS, a definitive role
of corticosteroids in the treatment of ARDS in adults
has not been established30. Hence, effective
pharmacologic therapy for established ARDS remains
controversial and extremely limited.
induced ILD, with the hospitalisation rate for ILD being
8.1 per 10,000 per year (0.08%)12. This discrepancy
between Japan and the western countries in the incidence
of lung toxicity was also tacitly echoed in a consensus
statement written by a multi-disciplinary panel of
rheumatologists and general practitioners across the U.K.
in late 2004. The consensus statement, published in early
2005, amidst the publicity aroused by the Japanese
clinicians/investigators, did not include lung toxicity on
their list of adverse events13.
A recent multivariate logistic regression risk analysis of
the large Japanese registry revealed the following risk
factors for leflunomide-induced lung injury: preexisting
ILD, with odds ratio (OR) of 8.17, loading dose
administration (OR 3.97), smoking history (OR 3.12) and
low body weight (OR 2.91)14. Fatality was most observed
in those with severe hypoxaemia requiring mechanical
ventilation, high C-reactive protein level,
hypoalbuminaemia, and persistent lymphopenia14.
Nevertheless, de novo cases of lefulnomide-induced lung
injury in the absence of the above-mentioned risk factors
do occur, as in our patient (Patient 1) and as reported in
the literature12.
Current Japanese recommendation places leflunomide
as a second-line drug not to be used in smokers, or
those with low body weight or with preexisting ILD.
Loading dose should not be given14. Careful monitoring
for drug toxicity is warranted, and when lung injury
develops, accelerated drug elimination using
cholestyramine and early use of steroids constitute the
mainstay of treatment8.
Amiodarone-induced ARDS
The pulmonary toxicity associated with amiodarone
therapy is a major factor limiting the widespread use of
this very effective anti-arrhythmic agent. Amiodarone-
induced lung disease occurs in about 5-10% of patients
receiving the drug15, manifesting itself in the form of
subacute onset of dyspnoea and CT findings of diffuse
interstitial thickening (known as subacaute interstitial
pneumonitis or fibrosis), or as nodular areas of
subpleural consolidation with histological features of
bronchiolitis obliterans organising pneumonia, or as
acute onset of dyspnoea and fever with CT findings of
dependent consolidation typical of ARDS16.
The pharmacokinetic properties of amiodarone
predispose the lung to amiodarone toxicity. Firstly,
amiodarone is lipophilic with a large volume of
distribution, hence the long elimination half-life at 45-60
days and likely storage in organs with high lipid content
such as fat, lung and liver15. Secondly, amiodarone's
principal metabolite, desethylamiodarone, accumulates
in peripheral tissues providing a sustained reservoir, to
the extent that concentrations measured in
unfractionated lung parenchyma significantly exceed
that of the heart, setting up the lungs up for toxic effects
of amiodarone17.
Mechanisms underlying lung toxicity have been poorly
understood, likely because of the heterogeneity of
amiodarone lung syndromes and corresponding
histopathological findings. Two prevalent hypotheses
have been (1) adaptative-immune-mediated
hypersensitivity reaction based on findings of an
VOL.11 NO.5 MAY 2006 Medical Bulletin
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Ventilatory Strategy for ARDS
The key advances in the management of ARDS in the
past decade lie largely in our better understanding of
the mechanisms underlying ventilator-associated lung
injury (VALI), which could further exacerbate the
ongoing insult to the lung. One important contributor
of VALI is regional alveolar overdistension
(volutrauma)31. Lung-protective strategy using low-
tidal volumes at 6 ml per kg of predicted body weight
have been proven in the ARDSNET study of over 800
patients to improve ARDS mortality from 40% to 31%32.
Hypercapnoea is deemed acceptable in this context.
Another contributor of VALI is repetitive alveolar
collapse with shearing (atelectrauma)33. However,
despite the interest in the use of high levels of PEEP for
addressing the problem of atelectrauma and for alveolar
recruitment, the clinical studies of high PEEP levels
have not been conclusive34,35. Current recommendation
on the use of PEEP targets at PEEP levels which can be
shown to improve rather than exacerbate the lung
mechanics36.
Unconventional Support for ARDS
Two unconventional therapeutic modalities for ARDS
have been hotly debated in the past decade: inhaled
nitric oxide (iNO) and prone positioning. Both
modalities have been aimed to address the key
pathophysiological derangement of ARDS: mismatching
of ventilation (V) and perfusion (Q) leading to gas
exchange impairment. iNO serves as a selective
pulmonary vasodilator, offering the theoretical
advantage of improving perfusion in areas of better
ventilation, thereby enhancing V/Q matching. Over 10
randomised trials on iNO have been conducted in the
past decade. Meta-analyses in 2003 and in 2007 both
showed no significant effect of iNO on hospital mortality,
duration of ventilation or ventilator-free days37. There
was however improvement in the oxygenation index
which persisted till day 4 of therapy. Renal toxicity was
noted. Routine use of iNO is not recommended. Some
clinicians may still consider iNO as a temporarising
measure for life-threatening hypoxaemia.
While iNO may not be readily available in a medical
centre, the application of prone positioning can be
achieved at the bedside of any ICU. The concept of
prone positioning (PP) as a treatment for ARDS arises
from the finding of atelectatic lungs in the dependent
dorsal regions in a supine patient with ARDS. The
reversal from supine to prone positioning allows
opening up of the atelectatic lungs, more favourable
lung mechanics, better V/Q matching and less VALI38.
Two recent meta-analyses seemed to have arrived at
similar conclusions about the clinical efficacy of PP: PP
did not improve survival despite an improvement in
oxygenation39,40. PP is therefore not recommended as
routine treatment for ARDS. However, a sustained
improvement in oxygenation may support the use of PP
in patients with severe hypoxaemia40.
Conclusion
ARDS represents a severe form of acute lung injury
requiring intensive care support. The two cases of
fulminant drug-induced ARDS presented here
represent triumph in combating a critical condition
using conventional as well as unconventional wisdom.
As drug-induced ARDS is largely a diagnosis by
exclusion, thorough search for other possible aetiologies
is a must. Clinicians who regularly use these two
drugs, leflunomide and amiodarone, need to keep
watchful vigilance on the development of lung toxicity
in those patients taking these drugs. Concommittant
exposure to other possible pulmonary toxins, such as
high-flow oxygen, needs to be avoided as much as
possible. Ventilatory support using low tidal volume
and optimal PEEP is considered the standard of care.
Inhaled nitric oxide and prone positioning are not
supported by the literature but nevertheless may serve
a temporarising role for those with severe hypoxaemic
failure. Pharmacotherapy for ARDS remains very
limited.
Table 1. Clinicopathological entities associated with drug-induced lung disease 4, 5
*GGO = Ground glass opacities
Clinicopathologic entity
Hypersensitivity pneumonitis
Eosinophilic pneumonitis
Nonspecific interstitial
pneumonia
Desquamative interstitial
pneumonia
Diffuse alveolar damage
Non-cardiogenic pulmonary
edema
Alveolar hemorrhage
Bronchiolitis obliterans
organizing pneumonia
CT findings
Bilateral GGO* and poorly
defined
centrilobular nodules
Peripheral alveolar infiltrates
Irregular linear opacities and
GGO in subpleural distribution
Bilateral GGO
Diffuse air-space consolidation
Dependent air-space
consolidation
Diffuse air-space consolidation
Patchy GGO,
consolidation and linear
opacities
Examples of drugs
Methotrexate, gold therapy,
cyclophosphamide, nitrofurantoin,
antidepressants
Methotrexate, sulfasalazine
minocycline, para-aminosalicylic acid,
nitrofurantoin, NSAIDs
Amiodarone, chemotherapy
Methotrexate, interferons, etanercept
Bleomycin, busulphan, mitomycin
Cytosine arabinoside, beta2 agonists,
blood products, narcotics
Oral anticoagulants, fibrinolytic agents,
platelet glycoprotein inhibitors
Busulfan, cyclophosphamide,
amiodarone, nitrofurantoin,
methotrexate
Prognosis
Favourable with
use of steroids
Favourable with
use of steroids
Poor, fibrosis likely
Favourable with
use of steroids
Poor; death in
50-60% patients
Favourable
Favourable
Favourable with
use of steroids
Respiratory failure
Yes but infrequently
Yes but infrequently
Usually subacute
Yes but infrequently
Yes typically
Yes typically
Yes typically
Usually subacute
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Low tidal volume ventilation has been shown to cause ventilator-associated lung injury.
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9.
10.
Questions 1-10: Please answer T (true) or F (false)
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Introduction
In 2004, the term Acute Kidney Injury (AKI) was
proposed to represent the entire spectrum of acute renal
failure (ARF) with clinical manifestations ranging from
a minimal elevation in serum creatinine to anuric renal
failure.1 The reported prevalence of AKI in critically ill
patients could be as high as 25% in some developed
countries, and only about 4% of this group received
renal replacement therapy (RRT), with an ensuing
hospital mortality up to 60%. Controversies exist in
many aspects of RRT for AKI despite decades of
development. However, definitive findings on the dose
of RRT were available last year. It is hoped that, with
the continued international collaboration, a clearer
picture would emerge in other areas of RRT.
Classification of Acute Kidney Injury
The RIFLE Classification2
In evaluating the clinical efficacy in AKI studies,
meaningful conclusions can only be drawn when there
is a common standard of reference. An expert panel
from the Acute Dialysis Quality Initiative (ADQI)
established a consensus definition called RIFLE in 2002
(www.ADQI.net). In summary, the acronym RIFLE
refers to three severity grades (in ascending order of
Risk, Injury and Failure) and two clinical outcomes
(Loss and End-stage renal failure). The severity grading
is based on the change from baseline of either serum
creatinine or urine output, whichever is greater. In the
subsequent years, RIFLE criteria have been validated by
different groups worldwide. With these new criteria,
the prevalence of acute kidney injury is 2-to-10 fold
greater than previously reported, ranging from 15.4 to
78.3%.3 RIFLE was also valuable in outcome prediction
and correlated well with mortality.3
The AKIN Classification [Table 1]
However, according to the data that have emerged
using RIFLE staging criteria, smaller changes in serum
creatinine than those considered in the RIFLE criteria
might also be associated with adverse outcomes. The
ADQI group, and representatives from three
nephrology societies (American Society of Nephrology,
International Society of Nephrology and National
Kidney Foundation) and the European Society of
Intensive Care Medicine met and decided to modify the
RIFLE criteria. A new classification system, the Acute
Kidney Injury Network (AKIN) Classification, was
developed. It retained the emphasis on changes in both
urine output and serum creatinine [Table 1]
Fluid overload unresponsive to diuretic treatment
Hyperkalaemia (>6.5 mmol/L or rapidly rising level)
Azotaemia (urea >36 mmol/L)
Severe acidaemia (pH <7.1)
Oliguria (urine output <200ml in 12 hours) or anuria
(urine output < 50ml in 12 hours)
Uraemia complications like bleeding, pericarditis or
encephalopathy
1.
2.
3.
4.
5.
6.
Drug overdose with dialysable or filtratable toxins
Patients requiring a large amount of fluid, parenteral
nutrient, or blood product but at risk of developing
pulmonary oedema or acute respiratory distress
syndrome
Cardiac failure
Hyperthermia or hypothermia (core temperature >
39.5oC or <30oC)
Severe dysnatraemia ([Na] >160 mmol/L or < 115
mmol/L)
1.
2.
3.
4.
5.
Indications & Timing for RRT
The usual indications for initiating RRT are:
However, in the past decade, the indications for RRT
have been extended widely to include many other non-
renal indications including: 4
Modified from RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease)
criteria. The staging system proposed is a highly sensitive interim staging system
and is based on recent data indicating that a small change in serum creatinine
influences outcome. Only one criterion (creatinine or urine output) has to be
fulfiled to qualify for a stage.
Given wide variations in indications and timing of initiation of renal replacement
therapy (RRT), individuals who receive RRT are considered to have met the
criteria for stage 3 irrespective of the stage they are in at the time of RRT.
a
b
Update of Renal Replacement
Therapy in the ICU
Dr. Wing-wa YAN
Dr. Wing-wa YAN
Director, Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital
MBBS(HK), MSc(CUHK), MRCP(UK), FRCP(Lond, Edin), FHKCP, FHKAM(Medicine)
Tabel 1. Acute Kidney Injury Network Classification/
Staging Systema
Stage
1
2
3b
Serum creatinine cr iter ia
Increase in serum creatinine of more than or
equal to 26.4 mol/l or increase to more than or
equal to 150% to 200% (1.5- to 2-fold) from
baseline
Increase in serum creatinine to more than 200%
to 300% (> 2- to 3-fold) from baseline
Increase in serum creatinine to more than 300%
(> 3-fold) from baseline (or serum creatinine of
more than or equal to 354 mol/l with an acute
increase of at least 44 mol/l
Urine output cr iter ia
Less than 0.5 ml/kg
per hour for more than
6 hours
Less than 0.5 ml/kg
per hour for more than
12 hours
Less than 0.3 ml/kg
per hour for 24 hours
or anuria for 12 hours
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The concept of 'prophylactic haemodialysis' was first
introduced in 1960. Patients with ARF receiving early
dialysis tended to have better wound healing, fewer
haemorrhages, improved nutritional support and better
survival. Since then, blood urea has been regarded as
one of the markers for the timing of intervention; the
threshold having decreased from 54 mmol/L in the
1960s to 33 mmol/L in 1970s.5 In the Conger's study of
post-traumatic ARF, five out of eight patients survived
after receiving early dialysis at a mean blood urea of 18
mmol/L; while only two out of 10 survived when
dialysis was initiated at a mean urea of 43 mmol/L.6
Survival benefit was also demonstrated in patients
suffering from ARF after cardiac surgery. One recent
study addressed early versus late intensive initiation of
continuous veno-venous haemodiafiltration (CVVHDF)
in patients with less than 100 mL urine in the 8
consecutive hours after operation.7 Early versus late
initiation (average lapse 0.88 vs 2.56 days) was
associated with reduced ICU stay (8 vs 12 days),
reduced ICU mortality (18 vs 48%), and reduced
hospital mortality (24 vs 56%).
Nevertheless, this observed benefit could not be
repeated in the Bouman's study.8 One-hundred and six
critically ill patients were prospectively evaluated to
assess the combined effect of early against late-initiation
as well as low-volume (LVHF) against high-volume
haemofiltration (HVHF). Patients were randomised into
one of the three groups: early HVHF (72-96 L/day),
early LVHF (24-36 L/day), and late LVHF (24-36 L/day).
On average, the early group started haemofiltration 7
hours after inclusion with the mean starting urea of 17.1
mmol/L; while the late group starting 42 hours after
inclusion with a mean urea of 37.4 mmol/L. There was
no difference in 28-day mortality nor renal recovery
among the three groups.
Thus, the best evidence on the optimal timing for
initiating RRT is still lacking and more studies are
needed to address these issues. Based on the currently
available data and the author's experience, early
initiation of RRT is preferable.
Dose of Renal Replacement Therapy
Dose Required
While in end-stage renal failure, the delivered spKt/V of
1.2 per dialysis (or urea reduction ratio of 65%) are the
accepted minimal standards in reducing
morbidity/mortality. The minimum dose for patients
with ARF has once been a great controversy in the field
of Intensive Care. Thanks to the recent release of two
large randomised control trials9,10 on the dose of RRT
for patients with ARF, it has been concluded that there
is no evidence to support the use of continuous renal
replacement therapy (CRRT) at a dose greater than
25mL/kg/hour. A summary of studies on dosing and
outcome in CRRT is listed in [Table 2].8-13
The ATN trial (Acute renal failure Trial Network)
published in 2008 in the United States did not show
any survival benefit with intensive dialysis therapy.9
This study recruited 1164 critically ill patients with
ARF to compare any mortality difference between the
conventional dose group with the more intense dose
group. The rate of death was similar; 53.6% in the
intensive therapy and 51.5% in the less-intense therapy
groups. There was no difference in the duration of RRT
or recovery of renal function.
Similarly, the RENAL trial (Randomised Evaluation of
Normal against Augmented Level of renal
replacement therapy in the ICU)10 conducted by the
Australian and New Zealand group showed no 90-day
mortality difference between the conventional dose
group and the intensive therapy group (44.68% vs
44.66%, p=0.993). This study recruited 1,465 patients
with severe ARF in ICUs, who were randomised to
receive post-dilutional CVVHDF at 25 mL/kg/h in the
conventional group against 40 mL/kg/h in the
intensive therapy group. The primary outcome of 90-
day mortality showed no difference between the two
dosages, and besides, all secondary outcome indicators
including ICU mortality, hospital mortality,
mechanical ventilation day, ICU length of stay,
hospital length of stay, RRT day, RRT dependence at
day 28 and day 90 also showed no difference.
High-volume Haemofil trat ion
(HVHF) in Sepsis Patients
For patients with severe sepsis or septic shock, there is an
overwhelming systemic overflow of pro-inflammatory
and anti-inflammatory mediators, leading to generalised
endothelial damage, multiple organ dysfunction and
altered cellular immunological responsiveness. The
removal of sepsis pro-inflammatory and anti-
inflammatory mediators may help in the treatment of
severe sepsis. Cytokines levels in sepsis were found to be
lowered only with HVHF (~45ml/kg/h) but not
conventional continuous veno-venous haemofiltration
(CVVH) (17ml/kg/h).14 Early animal studies and small
scale human trials provided good data on improving the
haemodynamic status and survival with HVHF. In the
Ronco study published in the Lancet in 2000, although
there was no overall survival difference between the two
groups with 35 and 45 ml/kg/h doses, a significant
survival difference was detected between these groups in
a subgroup analysis for patients with sepsis.11
A large randomised trial is going on to confirm this
unsettled dosing issue in RRT for patients with sepsis.
The IVOIRE study (hIgh VOlume in Intensive care)15 in
Europe will study the use of standard volume (35
mL/kg/h) against HVHF (70 mL/kg/h) in ARF patients
with septic shock. It aims to enroll 460 patients to detect a
15% absolute risk reduction in 30-day mortality
Circuit Patency in CRRT
In an international survey of 345 centres,16 the major
concerns of health care workers about CRRT was the use
of anticoagulant, frequent clotting of extracorporeal
circuit and the subsequent increased nursing workload.
CRRT downtime ranged from 8 to 28% of the total
treatment time.17 Clotting of circuit was the major reason
(74%) for the treatment loss. Therefore, it is essential to
maintain circuit patency in order to minimise the
discrepancy between prescribed and delivered doses.
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1. unfractionated heparin
2. low-molecular-weight heparin (LMWH)
3. citrate
4. prostacyclin / prostaglandin E1
5. nafamostat mesilate
6. direct thrombin inhibitor, e.g. r-hirudin
Commonly used anticoagulants in CRRT are:
However, if the use of systemic anticoagulation is
contraindicated, one of the alternatives is to flush the
system with saline and administer the replacement
solution pre-dilutionally. Even with these measures,
significant clotting is still encountered in up to 15 to
40% of patients. According to the recently published
BEST Kidney multi-national observational study,18
around one third of the patients received CRRT without
any anticoagulation. Among the various anticoagulants,
use of un-fractionated heparin ranked the highest
(42.9%), followed by regional citrate anticoagulation
(9.9%) and then nafamostat mesilate (6.1%)
Unfractionated heparin remains the standard systemic
anticoagulant with the benefit of wide clinical
experience, low cost, ease of use, ability to monitor the
level of anticoagulation and availability of antidotes like
protamine if needed. Heparin acts by binding to and
activating anti-thrombin III, which in turn inhibits
factors IXa, Xa, and thrombin. The anticoagulant effect
can be achieved by giving an initial bolus of 10 to 20
U/kg heparin; followed by continuous infusion of 3 to
20 U/kg/h to achieve 1.5 to 2 times of the normal
activated clotting time or activated partial
thromboplastin time. For patients at risk of bleeding, a
lower dose or a 'tight' heparin regimen with a bolus of 5
to 10 U/kg; followed by infusions of 5 to 10 U/kg/h can
be used.19
Low-molecular-weight heparin consists of only short
polysaccharide chains with average molecular weight in
the range of 3000 to 7000 daltons and its biological
activity is quantified by the extent of factor Xa
inhibition. Hence, dosing differs between different
brands of LMWH and the haemofilter used. With
respect to unfractionated heparin, LMWH has the
advantage of longer half-life, greater bioavailability,
dose-independent clearance, less heparin induced
thrombocytopenia and less bleeding because of less
impact on platelet function. In addition, the half-life of
LMWH is prolonged in renal failure and a single
injection at start of CRRT usually suffices for up to 5
hours.19 For example, enoxaparin 40 mg (4000-5000 anti-
factor Xa units or 60-70 anti-factor Xa units/kg) can be
given as a loading dose, followed by 10 to 40 mg every
6 hours if needed.19
TABLE 2. Summary of Studies on Continuous Renal Replacement Treatment (CRRT) Dosing and Outcomes
Study
Ronco
et al, 11
2000
Bouman
et al, 8
2002
Saudan
et al, 12
2006
ATN trial, 9
2008
Tolwani
et al, 13
2008
RENAL
study,
By ANZ
group 10
2009
No.
425
106
206
1124
200
1465
Randomisations
3 Arms comparing
3 different doses
(n=146 vs 139 vs 140)
3 Arms comparing
EHV vs ELV vs LLV
(n=35 vs 35 vs 30)
2 Arms comparing
2 different doses
(n=102 vs 104)
2 Arms comparing
intense vs less-intense
therapy
(n=563 vs 561)
2 Arms comparing
2 different doses
(n=100 vs 100)
2 Arms comparing 2
different doses
(n=743vs 722)
Prescr ibed
dose
(mL/kg/h)
20 vs 35 vs 45
48.2 vs 20.1
vs 19.7
25 vs 44
36.2 vs 21.5
(for
IHD/SLED,
6x/wk vs
3x/wk with
Kt/V of 1.2-
1.4 per
session)
20 vs 35
25 vs 40
Delivered dose
>85% prescribed
dose
Not mentioned
Achieved 87 %
vs 83% of the
delivered dose
35.8 vs 22.0
17 vs 29
22.0 vs 33.4
Pr imary
outcome
Survival at 15
days
Survival at 28
days; renal
recovery
28 days
survival;
90 days
survival
60 days
mortality
Survival to
ICU discharge
or 30 days
90 day
mortality
Results
41% vs 57%
vs 58%
74.3 % vs
68.8% vs 75%
(all except 1 in
ELV)
39% vs 59%
34% vs 59%
51.2% vs
48.0%
56% vs 49%
44.68 vs
44.66%
CRRT mode
Post-dilution CVVH:
QB 120-240 mL/min
Post-dilution CVVH:
EHV-QB 200 mL/min, QR 72 L/day
ELV-QB 100-150 mL/min, QR 24-36
L/day
LLV-QB 150 mL/min, QR 24-36L/day
Pre-dilution:
CVVH (low dose)-QB 100-125
mL/min, QR 1-2.5 L/h
CVVHDF (high dose)-QB 100-125
mL/min, QR 1-2.5 L/h, QD 1-1.5 L/h
CVVHDF:
Intensive-QB 150 mL/min, QD 1410
mL/h, QR 1390 L/h
Less intensive-QB140 mL/min, QD 820
mL/h, QR 83 mL/h
For both arms:
Haemodynamically unstable-
CVVHF/SLED
Haemodynamically stable-IHD
Pre-dilution CVVHDF:
Standard dose-QB 100-150 mL/min,
QD 1005 mL/h, QR 793 mL/h
High dose-QB 100-150 mL/min, QD
1831 mL/h, QR 1406 mL/h
Post-dilution CVVHDF
Qb >150 ml/min
CVVH denotes continuous veno-venous haemofiltration; CVVHDF continuous veno-venous haemodiafiltration; EHV early high volume; ELV early low
volume; ICU intensive care unit; IHD intermittent haemodialysis; LLV late low volume; QB blood flow; QD dialysate flow; QR replacement rate; SLED
sustained low-efficiency dialysis
Statistically significant
*
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Regional Citrate Anticoagulation (RCA)
Citrate chelates the calcium in the extracorporeal circuit
to mediate its anticoagulant effect.20-24 This citrate-
calcium complex is biologically inert and is partly
removed through the haemofilter. The remaining
calcium citrate enters the body and mixes with the
central venous blood. As the central venous blood flow
is much greater than the circuit blood flow rate, the low
ionised calcium concentration in the circuit is raised to
such a level that any systemic anticoagulant effect is
minimal. Therefore, citrate anticoagulation only exists
regionally within the circuit. The citrate-calcium
complex re-entered the body is dissociated back to free
ionised calcium and citrate. All the residual effects of
citrate are terminated by the liver, where it is
metabolised through the tricarboxylic acid cycle into
bicarbonate in a 1:3 ratio. To prevent filter clotting, a
pre-filter citrate concentration of 3.5 to 4 mmol/L is
needed to keep the ionised calcium concentration in the
circuit to below 0.25 mmol/L.19,21 Because of the net loss
of calcium in the form of citrate-calcium complex in the
ultrafiltrate, a small amount of calcium supplement is
needed. It is usually given intravenously via a separate
central venous line and its rate is titrated to give a
normal ionised calcium concentration.
Citrate is commonly formulated in 4% tri-sodium citrate
or anticoagulant-citrate-dextrose A (ACDA) or as
proprietary products like Gambro Prismocitrate 10/2
and Fresenius multiFiltrate Ci-Ca system (4% tri-
sodium citrate).
Although RCA is superior in keeping circuit patency,
the metabolic problems associated with it make it
unpopular. These include: hypernatraemia, metabolic
alkalosis and the potential for hypocalcaemia
(secondary to accumulation of citrate). The
contraindications for RCA are severe liver dysfunction
and massive blood transfusion. Its underlying rationale
is the increased risk of citrate accumulation causing
toxicity. Citrate toxicity should be suspected whenever
ionised calcium is persistently low or the total to
ionised calcium ratio is higher than 2.5.22 Symptoms of
hypocalcaemia include paraesthesia, nausea, cramps,
tetany, hypotension, decrease in cardiac output, or a
prolonged QT interval.19
In order to reduce the metabolic side effects related to
RCA, the concentrations of sodium and bicarbonate in
the replacement solution, during RCA setup, should be
carefully adjusted. Close monitoring of electrolytes
including sodium, potassium, arterial blood gases,
ionised and total calcium, during CRRT, is essential.
RCA has been adopted as the default mode for CRRT in
our department since 1995. Our experience with RCA is
promising. It is safe and well accepted by our doctors
and nurses. Overt metabolic complications have never
occurred.
Conclusion
AKI is common among the critically-ill and RRT is
frequently used to support these patients. Emerging
international consensus classification is available to
better stratify AKI patients so that future studies are
meaningful for comparison. Although the adequacy of
RRT dosing has been determined in recent good quality
trials, there still exist areas of uncertainties about RRT.
Further studies are needed to address the indications,
optimal timing of initiation and the types of
anticoagulants.
longer circuit / filter life
safe for use even in patients with bleeding
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Liver failure, regardless of aetiology, is a disease of
excessive mortality, and the only effective treatment so
far is liver transplantation. Because of organ shortage,
patient instability and various other reasons, liver
transplantation may not be performed in time in many
occasions. Throughout time, different artificial liver
support systems have been developed with the hope of
filling this time gap by temporarily supporting the liver
and stabilising the patient so that one can be bridged to
transplantation.
Molecular Adsorbents Recirculating System (MARS) is
a non-biological artificial liver support system
developed according to the prototype designed by
Stange and Mitzner at the University of Rostock,
Germany, in 19931. MARS is a form of blood
purification system that utilises albumin as dialysate to
remove protein-bounded toxins in patients of liver
failure2. The system consists of three interconnected
circuits. The patient's blood cycling in an extracorporeal
circuit is dialysed against an albumin circuit through a
specific dialyser running in countercurrent. The
membrane of the dialyser is impermeable to albumin
molecules, essential proteins or hormones, but it allows
the transport of bilirubin and other toxins across it by
means of a non-energy-dependent process known as
ligandification and deligandification into the albumin
dialysate circuit. The dialysate is then regenerated
online after passing through a charcoal adsorption
column and an anion exchange resin column. Hydro-
soluble toxins, urea, excessive electrolytes and fluid are
regulated through a third circuit, which can be a
standard haemodialysis machine or a continuous renal
replacement therapy (Figure 1).
Evidence
Evidence relating to the efficacy of MARS can be
categorised into three levels: biochemical efficacy,
physiological improvement, and clinical benefits. The
biochemical efficacy of MARS has been well proven.
Toxins as removable by MARS documented in the
literature include bilirubin, ammonia, aromatic amino
acids, tryptophans, short-chain fatty acids, bile acids,
GABA-like substances, nitric oxides and cytokines3.
Most of the toxins removable by MARS are implicated
in the development of hepatic encephalopathy, portal
hypertension or other inflammatory changes in liver
failure. Amongst all, reduction of bilirubin, either total
or direct, is the most consistent as demonstrated by all
studies. It should be noted that bilirubin, at least in
adult patients, is not a deadly toxin as such. Its use is
mainly regarded as a surrogate marker for other
hepatotoxins that are not routinely measured in daily
clinical practice.
The physiological benefits demonstrated by the MARS
system include lowering of intracranial pressure (ICP),
reduction of portal pressure, and improvement of
blood pressure and systemic vascular resistance.
Reduction of ICP in liver failure by MARS was first
reported in animal studies4 and subsequently also in a
case report5. Elevated ICP implies cerebral oedema
which is one of the most common causes of death in
patients with acute liver failure. Reduction of ICP
implies that cerebral oedema is under control and the
patient may be able to gain more time to bridge to
transplantation.
In patients with liver failure, particularly those with
cirrhosis, portal hypertension is a significant factor
contributing to ascites formation, variceal bleeding
and hepatorenal syndrome. MARS has been shown to
be able to reduce the hepatic venous pressure gradient,
an indirect measurement of portal pressure. This effect
is not only observed during treatment, but sustained
for up to 24 hours after MARS6. The mechanism of
reduction of portal pressure is unknown, but is
believed to be mediated through removal of vasoactive
substances like nitric oxide in the splanchnic
circulation by MARS.
The haemodynamic benefits brought about by MARS in
patients having liver failure include raised mean arterial
pressure, increased systemic vascular resistance, and
reduced cardiac output. Haemodynamic effect is
particularly prominent in patients with cirrhosis during
treatment7,8. In patients with acute liver failure,
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Figure 1 :The MARS circuit (with permission from
Gambro, Inc)
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increased vascular tone could also be observed, but the
result is not as sustained9. These findings illustrate that
MARS is haemodynamically well tolerated and would
not cause hypotension as such. From our experience,
however, we find transitory hypotension rather
common at the beginning of treatment, and small doses
of vasopressor are frequently needed to sustain blood
pressure. We attribute this to release of cytokines
secondary to platelet activation and change in rheology
of blood10 circulating through the extracorporeal
system.
The effects of MARS on two most common
complications of liver failure have been studied.
Mitzner et al. reported a significantly lower mortality
rate in patients with type 1 hepatorenal syndrome
treated with MARS compared with those having
standard medical therapy11. The major shortcoming of
this study was that there were only 13 patients involved
and in fact only one patient in the treatment survived
beyond 30 days. Earlier studies of MARS on hepatic
encephalopathy were mainly non-randomised studies
and reported lower mortality in treatment groups12.
Hassanein et al. reported the use of MARS in patients
with severe hepatic encephalopathy in a large-scale
randomised controlled trial and concluded that the
treatment was associated with earlier and more
frequent improvement in encephalopathy grading13. It
should be noted, however, that the trial was not
designed to address the impact of MARS on survival.
MARS is not without complications. The most common
complication of MARS is platelet reduction. In our
experience, the drop in platelet per treatment is around
5 to 10%, but it may be up to 20% in some cases.
Though it might not seem significant in most patients
with platelet count more than 100x10^9/L, it does raise
concern in cirrhotic patients with splenomegaly in
which they commonly have thrombocytopenia to start
with and when repeated treatments are needed. We
empirically give platelet transfusion before MARS to
patients with platelet count less than 30x10^9/L. In our
experience, four major bleeding episodes might have
been related to MARS (2 intracranial bleeding, 1
variceal bleeding and 1 intra-abdominal bleeding after
liver transplantation). However, given the inclination of
developing these complications in such critical patients,
it may be unjustifiable to attribute occurrences of these
episodes to MARS. Worldwide, the opinion is that
MARS treatment is safe and does not cause additional
bleeding risk.
Other documented complications of MARS include
hypoglycaemia during treatment14, electrolyte
disturbances15, and non-cardiogenic pulmonary
oedema16. As MARS is one form of extracorporeal
circuit, it shares the potential complications that
extracorporeal circuits usually have, including catheter-
related infection, haematoma and circuit thrombosis.
Anticoagulation in treatment by MARS is a difficult
topic. In our unit, we have moved from no
anticoagulation to the use of low molecular weight
heparin, and then to heparin priming in which the
system is flushed with heparin saline before use. Given
the nature of the disease of patients treated, we have
not used systemic anticoagulation, albeit it is claimed to
be safe according to other centres' experience. The
coagulation profile of patients with liver failure varies
significantly and represents the interplay between
thrombocytopenia, platelet dysfunction and also
reduced synthesis of clotting factors and antithrombin
from liver. In order to develop a tailor-made
anticoagulation strategy, some researchers have
advocated the use of thromboelastography (TEG) to
monitor these patients during treatment17,18. We have
also tried to apply this monitor in our practice, but
because TEG interpretation is in itself open to a lot of
debate, we feel that it is still a research tool rather than
for routine clinical use. Circuit thrombosis is not
necessarily due to inadequate anticoagulation. Circuit
blood flow and turbulences, as well as position and
properties of the dialysis catheter, could be contributing
factors to inadequate anticoagulation.
Management Pitfalls
MARS is by no means a salvage treatment for liver
failure. The most serious management pitfall is
implementing MARS as a last resort hoping that the
treatment can reverse the detrimental effects of liver
failure at a time when the patient is already moribund.
In our practice, we employ MARS as an early
intervention to prevent deterioration, preferably when
the patient is not too ill. We render MARS treatment to
those showing rapid velocity but not high absolute
value in biochemical deterioration, those with grade 2
hepatic encephalopathy, and those with hepatorenal
syndrome with urine output still more than
0.5ml/kg/hr. We believe it is at these time points that
MARS can alleviate organ damage and retard
progression of the disease through hepatotoxin
removal. On the contrary, if MARS treatment is
rendered late in the course of liver failure, the benefit of
hepatotoxin removal will become minimal amidst the
overwhelming cascade of physiological damages
brought about by multi-organ failure19.
Another management pitfall is indiscriminate use of
MARS for all patients with liver failure. In fact, MARS
is not applicable to all patients; only a selected few can
benefit from it. The selection criteria for MARS
candidates in our unit are listed in Table 1. Based on
these criteria, less than 25% of the patients admitted
with liver failure to our intensive care unit are eligible
for the treatment. Certain subgroups of patients, such as
those with acute decompensated Wilson disease, have
appeared to respond particularly well to MARS20.
Selection of suitable candidates and initiation of MARS
at appropriate timing are the two most important
factors to improve the success rate of MARS treatment.
The third management pitfall is utilising MARS as a
means to reverse liver failure. Although native liver
recovery with MARS has been reported in the literature
and also occasionally encountered in our experience, it
is unpredictable as to which patients will respond
favourably. It is therefore inappropriate to commend
the treatment as one which can promote liver recovery.
In our centre, the sole objective of performing MARS is
to stabilise patients' conditions and to bridge them to
transplantation. It should be clearly explained to
patients who are undergoing MARS but not aiming for
liver transplantation that the treatment would only
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bring about short-term improvement to their
conditions. Hopefully, recognition and appropriate
future consideration of these management pitfalls will
offer possibilities for further refinement of the use of
MARS in patients with liver failure.
Conclusion
Since MARS was first launched into clinical application
in year 2000, research materials published on this topic
have exceeded 500, mostly descriptive studies with only
a handful of randomised trials amongst them. Given the
lack of concrete evidence to demonstrate the survival
benefit of MARS, it is understandable that clinicians are
skeptical to commit to such treatment which is
expensive to run, has a complex operative procedure,
and, most importantly, not without risk. It should be
noted, however, that liver failure is a disease associated
with high mortality and limited treatment options. Any
suggestion or evidence, despite being observational or
uncontrolled, should therefore not be overlooked and
neglected casually. Moreover, the lack of conclusive
result from randomised controlled trials could also be
due to fallacies and limitations of study methodology.
Heterogeneity of the disease, existence of confounding
factors, e.g. availability of liver transplantation, and lack
of reliable tools to prognosticate patients and to monitor
treatment efficacy are all factors that need to be
considered in the design of studies on MARS.
In summary, utilisation of MARS treatment requires a
comprehensive understanding of its benefits and
limitations if optimal outcome is to be achieved. Further
studies to delineate and refine the clinical indications,
timing of initiation and operative details are needed to
give clinicians a better idea of how to implement such
service in practice.
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Acute circulatory failure resulting in cardiogenic shock is
a common problem encountered in the intensive care
unit. Cardiogenic shock is defined by the presence of the
following haemodynamic parameters: sustained
hypotension (systolic blood pressure <90mmHg or mean
arterial pressure of 30mmHg below basal level),
adequate or elevated left ventricular (LV) filling pressure
(e.g. left ventricular end-diastolic pressure >18mmHg or
right ventricular end-diastolic pressure or pulmonary
artery wedge pressure > 15mmHg) and reduced cardiac
output (cardiac index <1.8L/min/m2 without support or
<2.0-2.2 L/min/m2 with support). Clinical manifestations
of cardiogenic shock include signs of poor tissue
perfusion such as cold extremities, oliguria and/or
clouded sensorium, in the setting of myocardial
dysfunction. Causes of cardiogenic shock include acute
myocardial infarction with or without mechanical
complications (e.g. ventricular septal rupture, papillary
muscle rupture with acute mitral regurgitation,
contained free wall rupture), acute myocarditis, tako-
tsubo (or stress-induced) cardiomyopathy, acute valvular
regurgitation, or any other cause of acute severe left
ventricular (LV) or right ventricular (RV) dysfunction.
The mainstay of treatment for cardiogenic shock is
pharmacological support using inotropic agents, such
as dobutamine, dopamine and norepinephrine, and
phosphodiesterase inhibitors, such as milrinone. These
agents improve short-term haemodynamics at the
expense of increased oxygen demand by increasing
myocardial ATP consumption, which may be
deleterious over long-term. Calcium-sensitising agents
with inodilatory properties such as levosimendan,
which does not increase oxygen demand and is less pro-
arrhythmogenic, have been shown to have a statistically
non-significant but consistently lower mortality than
dobutamine at six months in the treatment of acute
decompensated heart failure1. Another agent which
may be used to treat acute decompensated heart failure
is a recombinant B-type natriuretic peptide called
nesiritide. However, pooled analysis of randomised
controlled trials showed increased risk of death at 1
month2 and worsening renal function with nesiritide
compared to usual therapy3.
Mechanical Circulatory Support
In circumstances where a potentially reversible cause of
acute heart failure has been identified or where cardiac
surgery or transplantation is considered an option for
refractory heart failure, mechanical circulatory support
systems are available which can maintain the patient
untildefinitivetreatment is instituted. Mechanicalcirculatory
support can be life-saving in acute cardiogenic shock and
particularly useful as a bridge to recovery in cases of
fulminant myocarditis. There is evidence that patients
with fulminant myocarditis, i.e. those with severe
haemodynamic compromise, rapid onset of symptoms
and fever, have a better long-term prognosis than those
with acute nonfulminant myocarditis if they survive the
initial period of cardiogenic shock4. Therefore, in these
patients, an aggressive approach including mechanical
circulatory support is warranted. Time from onset of
illness to recovery of ventricular function in fulminant
myocarditis usually takes 2 to 3 weeks5. Mechanical
circulatory support includes placement of intra-aortic
counterpulsation balloon pumps (IABP), extracorporeal
membrane oxygenation systems (ECMO), and
ventricular assist devices (VAD).
Intra-aortic Balloon Pump (IABP) or
Counterpulsation
Intra-aortic balloon pump (IABP) is the most commonly
used mechanical support for cardiogenic shock. The IABP
is commonly inserted percutaneously through the femoral
artery (Figure 1) but, in patients with peripheral vascular
disease, it may be inserted through the brachial artery6. By
synchronising inflation and deflation to the patient's
cardiac cycle, the IABP improves coronary and peripheral
perfusion during diastolic balloon inflation and augments
left ventricular performance during systolic balloon
deflation by reducing the afterload (Figure 2).
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Figure 1. The IABP is inserted percutaneouly via the femoral
artery and positioned in the thoracic aorta distal to the left
subclavian artery and proximal to the renal arteries
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Apart from left ventricular failure and cardiogenic
shock, indications for IABP include support of high risk
patients for percutaneous coronary intervention, cardiac
surgery for post-myocardial infarction ventricular
septal defect or acute mitral regurgitation, stabilisation
of heart failure patients undergoing general anaesthesia
and bridge to heart transplant. Its use is contraindicated
in severe aortic valvular insufficiency which may
worsen during diastolic regurgitation, aortic dissection,
peripheral vascular disease and tachyarrhythmias.
Vascular complications associated with the use of IABP
include limb ischaemia, aortic or arterial injury such as
perforation and dissection, femoral artery thrombosis,
peripheral embolisation, and visceral ischaemia. Other
complications may be balloon related (such as incorrect
positioning, gas embolisation) or related to infection or
entrapment. In patients with peripheral vascular
disease and diabetes, sheathless method rather than
sheathed technique should be used7.
E x t r a - c o r p o r e a l M e m b r a n e
Oxygenation (ECMO)
ECMO is a form of extracorporeal life support whereby
an external pump system carries the venous blood from
the large central veins of the patient to an oxygenator (a
gas exchange device) where the blood becomes
enriched with oxygen and has carbon dioxide removed.
The oxygenated blood then re-enters the patient's
circulation, either through the aorta or arterial system
(so-called veno-arterial ECMO) (Figure 3) or through
the venous system (veno-venous ECMO). Veno-
arterial ECMO provides support for severe cardiac
failure with or without respiratory failure and can be
set up by using peripheral cannulation of the femoral
artery and vein (Figure 4), so-called percutaneous
cardiopulmonary support system (PCPS). Veno-arterial
ECMO may be applied for the short-term management
of cardio-respiratory failure or cardiac failure refractory
to inotropic and IABP support. Common indications
include acute fulminant myocarditis8, severe acute
respiratory distress syndrome (ARDS)9, acute
decompensated dilated cardiomyopathy, ischaemic
cardiogenic shock, drug overdose or sepsis with
profound cardiac depression and as a bridge to longer-
term ventricular assist device10. Veno-venous ECMO
involves return of oxygenated blood to the venous
system of the patient, usually the right atrium via the
internal jugular vein, and is the preferred mode of
support for isolated respiratory failure, such as ARDS11.
In ARDS, ECMO provides life support without reliance
on high-pressure high-oxygen mechanical ventilation
for gas exchange, thereby reducing the release of
inflammatory mediators from the damaged native lung,
and buys time necessary for the lung to heal.
The major components of ECMO involve the blood
pump ('the heart') and the oxygenator ('the lung').
Previously roller pumps were standard for ECMO
therapy but the mechanical stress results in rupture and
embolism of tube particles. These complications are
avoided with the use of centrifugal pumps. The
Figure 2. Inflation and deflation of the IABP are synchronized
to the patient's cardiac cycle - A. With balloon inflation during
diastole, there is increased coronary artery blood and systemic
perfusion; B. With balloon deflation during systole, oxygen
demand is reduced, resulting in increased stroke volume and
reduced afterload.
Figure 3. Different components of an ECMO system - the main
console controls the flow rate of the centrifugal blood pump,
which drives the venous blood from the patient through the
oxygenator prior to returning the blood to the arterial side of
the patient's circulation.
Figure 4. Blood is accessed from the large central veins such as
the inferior vena cava and returned to the arterial system in the
aorta after passing through the oxygenator of the ECMO
system.
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duration of ECMO support depends on the type of
oxygenator used. With silicone-membrane or
microporous hollow-fibre oxygenators, plasma leakage
typically occurs after a few days, necessitating circuit
changeover. However, with diffusion membrane
oxygenators such as the QuadroxD (Jostra
Medizintechnik AG, Hirrlingen, Germany), the hollow-
fibre technology utilises a true non-microporous
membrane and avoids plasma leak problem. The
system is ideal for prolonged perfusion up to 14 days
with the longest duration reported to be 46 days12.
Like the IABP, the PCPS is also contraindicated in aortic
dissection and severe aortic valve regurgitation.
Potential complications associated with the use of
ECMO include vascular complications, haemolysis,
mechanical problems with clots or air in the system,
oxygenator thrombosis and bleeding tendency with use
of heparin.
In case of IABP failing to support the patient, PCPS or
V-A ECMO can immediately provide adequate
perfusion to all organs irrespective of the lung
condition. However, PCPS cannot augment coronary
blood flow and may increase left ventricular afterload.
Combination of IABP and PCPS is clinically feasible and
has been shown in animal models to have important
advantages over PCPS alone, especially in ischaemic
cardiomyopathy13,14. Combined use of IABP and
ECMO reduces left ventricular wall stress and oxygen
consumption while increasing the end-systolic
elastance13 and reduces tissue acidosis and myocardial
necrosis14.
Ventricular Assist Devices (VAD)
Patients with advanced heart failure in New York Heart
Association class III and IV may be classified into seven
clinical profiles in the Interagency Registry of
Mechanically Assisted Circulatory Support
(INTERMACS) to allow optimal selection for
mechanical circulatory support, especially ventricular
assist devices (VAD). 80% of such devices are being
used in the two profiles with the highest levels of
clinical compromise, namely those "crash and burn"
patients (INTERMACS profile 1) and "sliding on
inotropes" patients (INTERMACS profile 2)15. There are
many types of VAD, with the first-generation VAD
being pulsatile devices, the second-generation VAD
being the axial flow pumps and the third-generation
VAD being centrifugal pumps which are bearingless
and designed for long-term support. In the past, use of
the extracorporeal or implantable VAD requires
surgical implantation in the operating theatre.
Recently, VAD which may be inserted percutaneously
have been developed for clinical use. For example, the
TandemHeart Percutaneous Ventricular Assist Device
(pVAD) is an extracorporeal continuous-flow
centrifugal pump. A cannula is inserted through the
femoral vein, across the interatrial septum and into the
left atrium. The TandemHeart pump withdraws
oxygenated blood from the left atrium and returns it to
one or both femoral arteries via arterial cannulas
(Figure 5). Compared with IABP, the pVAD can
provide better haemodynamic improvement, in terms
of increased cardiac output, reduced pulmonary wedge
pressure and higher mean
arterial pressure16,17, and
lower serum lactate level17.
Potential complications with
this device include limb
ischaemia, disseminated
intravascular coagulation
(DIC) , bleeding from
cannulat ion s i te and
infection. Another device
called the Impella Recover
LP 2.5 is a minimally
invasive catheter-based
ventricular assist device,
which is inserted using the
Seldinger technique through
the femoral artery. The tip
of the catheter contains a
"pigtail" which rests in the
left ventricle18.
Evolving Role of Mechanical
Circulatory Support
Nowadays, VAD is not only used as a bridge to heart
transplantation in severe heart failure but increasingly
used as a bridge to myocardial recovery or as
destination therapy (i.e. for permanent use in patients
who are not candidates for heart transplantation).
There is evidence that, in some severe heart failure
patients, prolonged complete unloading of the left
ventricle (LV) with VAD may lead to structural reverse
remodelling and functional improvement of the LV.
This is true not only in myocarditis patients19 but also in
non-ischaemic dilated cardiomyopathy patients20. The
time frame for myocardial recovery can vary from
weeks to months. Currently the use of implantable
long-term VAD is associated with major complications
such as embolic stroke, mechanical device failure,
infection and need for sternotomy. Development of
bearingless centrifugal pumps, smaller devices and
partial cardiac support system which can be implanted
with a minimally invasive procedure21 will hopefully
minimise some of the problems.
Conclusion
At present, IABP, ECMO and VAD are available as
mechanical circulatory support for cardiogenic shock.
The IABP is convenient to be applied but can only
provide limited additional cardiac output, which may
not be adequate for critical situations. ECMO can
provide total circulatory support but suffers the
drawback of extracorporeal circulation such as
activation of cellular elements and the need of an
oxygenator. The duration of use is limited to 2 to 6
weeks. Implantable VAD has the potential to provide
Figure 5. Diagramatic
r ep r esentat ion o f a
percutaneous ventricular
assist device (pVAD) which
withdraws oxygenated
blood from the left atrium
and returns it to the femoral
artery via arterial cannula
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Infectious disease emergencies (IDEs) are not uncommon.
However, even in a classical infectious diseases textbook,
only intracranial infection, bacteraemia, and fulminant
pneumonia are included in the relevant chapter. In
practice the spectrum of IDEs manifesting in an inpatient
setting is much wider1,2. We define or will define as any
clinically and microbiologically documented infection
that by itself or as a complication of its treatment is
liable to result in (i) irreversible local tissue or organ
damage, permanent functional loss, or (ii) imminent
death without urgent medical or surgical intervention
or progressive system inflammatory response
syndrome, to the extent that advanced life support or
intensive care would soon be required.
Strategies in the Diagnosis of IDE
Constant vigilance, a systematic approach to any clinical
problem, and timely consultation will enable early
detection of conditions requiring urgent treatment, so
that optimal management may be implemented early to
prevent irreversible complications or death. All infections
may initially be minor and appear innocuous, such as
cellulitis developing from an inapparent skin wound.
However, if the initial infective process is uncontrolled
by the host defence mechanisms or appropriate therapy,
it may result in potentially life-threatening diseases, such
as group A streptococcal necrotising fasciitis or
Streptococcus suis meningitis. It is essential that the
diagnosis be made when the area of necrosis or extent of
meningeal involvement is still limited. At this early stage,
even though the pathology has been established and
bacteria could be isolated from tissues or CSF, the clinical
signs may not be typical. Nevertheless, the benefit of
correct treatment at this stage is the greatest. Similarly,
antibiotic-induced morbilliform rash is not an IDE, but
erythema multiforme involving the mucosa heralds one.
It may be too late if an IDE is declared only when frank
skin exfoliation or gastrointestinal bleeding occurs. The
clinical examples of IDEs encountered in our clinical
consultation service are listed in Table 1.
Causes for Failure to Make an Early
Diagnosis
Failure to recognise an emergency was related to
several factors, the commonest being a presentation that
does not conform to classic descriptions of the disease,
such as deafness rather than neck rigidity in acute
pyogenic meningitis. Furthermore, typical features may
present in an atypical clinical setting. For example, CMV
retinitis is a well-known complication in HIV-infected
patients, requiring urgent anti-viral treatment, but
suspicion of this entity may not be raised in non-AIDS
cases. This illustrates the need to account for each acute
clinical manifestation despite apparent incongruence.
Sometimes, diseases usually not directly related to the
clinical specialty of the referring clinicians may also be
missed. In this era of specialisation, clinicians often rely
on their colleagues to deal with problems that do not fall
strictly within their specialty. Thus, a considerable
number of adverse reactions to antimicrobial agents were
not recognised early.
Clinicians may also face difficulties with uncommon
organisms and their associated pathology such as
Bartonella henselae, rickettsiae, Leptospira, Haemophilus
aphrophilus, and Vibrio vulnificus. Similarly, rare
complications of common infections may not be
appreciated such as Clostridium difficile-related toxic
megacolon. A better liaison between the infectious disease
specialist and the clinician can enable mutual exchange of
knowledge and experience and ultimately result in
improved care of patients in the early stages of an IDE.
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Table 1. Examples of infectious disease emergencies encountered in
the clinical consultation service at the Department of
Microbiology, Queen Mary Hospital.
Organ system
Central nervous system
and eye
Cardiovascular system
Upper respiratory tract
Lower respiratory tract
and thorax
Alimentary system and
peritoneum
Skin and soft tissue
Bone and joint
Systemic
Antibiotic-induced
Examples
Acute meningitis
Cerebral and epidural abscess
Cytomegalovirus retinitis
Subdural empyema, endophthalmitis, cavernous
sinus thrombosis, VZV anterior uveitis and keratitis,
rhinocerebral mucormycosis
Infective endocarditis
Infected aortic aneurysm or graft
Pyopericardium, cardiac tamponade
Imminent upper airway obstruction, e.g. mucositis,
abscess
Fungal sinusitis, rhinocerebral mycosis
Fulminant pneumonia
Miliary tuberculosis
Cavitary pneumonia with pneumothorax
Massive haemoptysis (aspergillosis in old
tuberculous cavity)
Procedure-related mediastinitis
Tertiary peritonitis
Toxic megacolon (amoebic, typhoid)
Neutropenic ileocaecitis
Emphysematous cholecystitis
Necrotising fasciitis and Fournier's gangrene
Gas gangrene
Orbital cellulitis
Pyogenic arthritis
Sepsis in immunocompromised patients including
post-splenectomy sepsis and neutropenic sepsis
Severe sepsis and others*
Hepatitis, renal failure
Xanthopsia, hearing loss
Allergic reactions
Convulsion
Including gas gangrene, tetanus, severe falciparum malaria, hantavirus haemorrhagic fever
with renal syndrome, chickenpox in an oncology patient, dengue haemorrhagic fever,
bleeding due to severe thrombocytopenia as a result of rubella and infectious mononucleosis,
toxic shock syndrome, perinephric abscess, emphysematous pyelonephritis, pyonephrosis.
*
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ReferencesManagement of IDE
Regarding the care of patients with IDEs, the 
commonest contribution of the infectious disease 
specialist is to advise on the choice of appropriate 
antimicrobials. The proficiency of infectious disease 
specialists in antimicrobial chemotherapeutics also 
enables them to initiate modification of the dosage or 
route of administration as appropriate. Another 
contribution of the infectious disease team is the 
delineation, after thorough evaluation of patients and 
further investigations, of problems that were not 
apparent to the referring clinician. For example, 
necrotising fasciitis due to V. vulnificus is known to be 
rapidly progressive, and an early diagnosis can make a 
significant difference in the eventual outcome. Our 
experience is that needle aspiration is pivotal in 
establishing an aetiological diagnosis and indicating the 
choice of antimicrobials. Early extensive debridement, 
as guided by the Gram smear of the resection margin, is 
crucial for a favourable outcome. In the long run, the 
infectious disease team will help to raise the awareness 
of this IDE, alerting clinicians to future occurrences of 
similar conditions, and recognising the early outbreak 
of deadly disease like SARS3.
Clues to Early Recognition of IDE
Patients with a systemic inflammatory response should 
be carefully evaluated for any underlying focus of 
infection that may not be apparent initially. 
Occupational history, local signs, or subtle radiological 
findings can also be useful pointers to the diagnosis and 
its emergency nature. Any condition involving vital 
organs such as the central nervous system (brain, spinal 
cord, and eye), the cardiovascular system (especially 
heart valves), and the upper airway should alert 
clinicians to the potential for irreversible damage due to 
an infection. Emergencies can arise as a result of serious 
toxicity from treatment; they are usually due to drugs, 
including hypersensitivity reactions, potentially 
irreversible organ toxicity, or other side effects. 
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Introduction
Critically ill patients in the intensive care unit (ICU)
requiring mechanical ventilation frequently experience
pain, anxiety, sleep deprivation and distress. Sedation
and analgesics are commonly used to provide comfort
and relieve pain. Commonly used agents include
benzodiazepines, propofol, opioids and the newer
agents, remifentanil and dexmedetomidine.
There is now an increasing awareness that important
complications from sedative agents and the way they
are used, can occur.1 Oversedation can prolong weaning
from ventilation and ICU duration of stay.2
Undersedation may contribute to increased sympathetic
activity, myocardial ischaemia, poor ventilator
synchrony, hypercatabolism, immunosuppression and
accidental dislodgements of lines and tubes. Finally,
sedation and analgesia may increase delirium, which
can occur in up to 80% of ICU patients, without
achieving increased comfort.
Current practice varies widely.1,3 New trends and
research are therefore focused not only on which is the
best pharmacological agent, but also on monitoring the
depth and adequacy of sedation and protocols
sedation use.
Indications for Sedation
Appropriate evaluation and management of causes of
distress are essential to optimal management of sedation.
Preexisting medical conditions such as alcohol or
substance abuse, chronic sedative use, psychiatric illness,
alzheimers, gout, chronic pain may contribute to the
experience of distress and influence choice of agent.4
Identifying new causes of pain related to the acute illness
is also crucial. Management of root causes such as
bedsores, wound infections and changing medical
conditions should not be masked by use of sedatives.
Simple measures such as frequent turning, removing
restraints if possible, or minimizing light and noise to
allow night time sleep patterns may also improve patient
comfort. Communication and explanation to the patient
during interventions can significantly allay anxiety.
Pharmacological intervention should be considered
only after treatable predisposing and precipitating
factors have been managed, prior psychiatric and pain
medications have been resumed, and the ICU
environment has been optimized for patient comfort.
Monitoring of Sedation and Analgesia
Pain evaluation in the ICU is generally poorly done.
Patient self reporting with a visual analogue scale (VAS)
is most preferred, although often difficult in the ICU
setting. Table 1 shows the Critical Care Pain
Observation Tool.5
Sedation scales such as the Ramsay Sedation Scale, The
Richmond Agitation Sedation Scale (RASS), Sedation
Agitation Score, and Motor Activity Assessment Scale
are shown in Table 2 and have all been validated for use
in the ICU.6 Whilst such sedation scales allow better
documentation, reduced sedation and analgesic use,
and shorter duration of ventilation, widespread use has
not yet been adopted.6,7
Objective measures of depth of sedation include the use
of electroencephalograms (EEG), bispectral index (BIS)
and the Narkotrend index.6 None of these are
commonly employed.
Sedative and Analgesic Agents
Drugs used for analgesia and sedation in the ICU are
compared in Table 3. Choices of sedative agents are
determined by the underlying cause of discomfort, the
sensitivity of patients to the agents and the likely length
of sedation required. Optimal strategies match the
patients needs with a particular drugs' pharmacokinetic
and pharmacodynamic profile. The context sensitive
half times indicate the change in half time clearance of a
drug, when the preexisting duration of infusion is
considered. During prolonged infusions, drugs are
redistributed to saturate body compartments, and when
stopped, clearance is prolonged.
IV Induction Agents
Propofol had been extensively used as an ICU sedative
infusion. With a high clearance, propofol sedative
infusions allowed shorter times between termination of
infusion and extubation. A recent meta-analysis8
concluded using propofol infusion reduced duration of
mechanical ventilation and length of ICU stay only
when compared with long acting benzodiazepines, but
not when compared with midazolam.
Side effects include myocardial depression, reduced
systemic vascular resistance, hypertriglyceraemia,
elevated amylase levels and green urine.
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Its' use has been curtailed by the increasing awareness of
propofol infusion syndrome. This results in severe
metabolic acidosis and muscle necrosis, likely due to
impairment of fatty acid chain oxidation and inhibition
of oxidative phosphorylation in mitochondria.
Thiopentone infusions are mainly used in refractory
status epilepticus or refractory intracranial hypertension.
Hepatic enzyme saturability means zero order kinetics
with prolonged infusions resulting in prolonged
wakening times, as well as myocardial depression and
immunosuppression.
Ketamine infusions are used in resistant status
asthmaticus. A phencyclidine derivative, it produces a
dissociative anaesthesia, analgesia and amnesia. Side
effects include sympathetic stimulation with increased
cardiac work, and delirium.
Benzodiazepines
Benzodiazepines bind to the GABAA ligand gated Cl-
channel to produce sedation and hypnosis. Midazolam
has the highest clearance, and minimal haemodynamic
effects and is the most commonly used sedative
infusion.3,6 Concerns include increased delirium,
dependence and withdrawal agitation.
Opioids
Opioids produce analgesia, narcosis and anxiolysis. Side
effect concerns include respiratory depression, histamine
release, bradycardia, hypotension, nausea and vomiting
and poor gastric motility. Withdrawal agitation is also a
concern.
There are differences in specific agents. Morphine's
histamine release contribute to increased pruritis and
potential bronchospasm, compared with fentanyl.
Accumulation after continuous drug infusion can lead to
prolonged drug effects.
Remifentanil is an ultrashort acting ester opioid
commonly used in anaesthesia. It's metabolism is non
organ dependant and is by nonspecific blood and tissue
esterases to an inactive metabolite. This means it has a
stable context sensitive half time (3-10 mins). Offset is
therefore independent of length of preceding infusion.
Studies have shown shorter weaning from mechanical
ventilation and duration of ICU stay compared with other
opioids.9 Increased relative costs is a concern. Concerns
are similar to those of other opioids and include
bradycardia, hypotension and acute onset withdrawal. In
addition because of rapid offset of effects, alternative
analgesia may be required when infusions are stopped.
Loading dose is 1 g/kg over 1 minute. Infusion
concentrations are commonly 20, 25 or 50 g/ml. Infusion
rates of 0.1-0.15 g/kg/min can be continued and
increased by 0.025 g/kg/min at 5 min intervals to a
maximum rate of 0.2 g/kg/min.
2 Agonists
Dexmedetomidine is a new potent 2 agonist acting in the
locus ceruleus, causing inhibiting sympathetic
stimulation, analgesia, sedation, without causing
respiratory depression. Studies have shown improved
weaning in patients with agitation from opioid or
benzodiazepine withdrawal.10 Dexmedetomidine was
compared with midazolam in 375 mechanically
ventilated ICU patientsfor up to 30 days of continuous
infusion.RASS scores were kept between -1 to +1.11
Riker et al . found less delirium, (54% in
demedetomidine group vs 76.6% in midazolam group,
p<0.01) in less tachycardia and hypertension, and less
time on ventilators (3.7days in dexmedetomidine
group vs 5.6days in midazolam group p<0.05).
Delirium has been independently associated with
cognitive impairment and 6 month mortality.
Concerns include hypotension, bradycardia, and
absence of approval for infusions longer than 24 hours.
There is a study underway by the US NIH clinical
trials group comparing dexmedetomidine and
propofol for sedation of ICU patients.
Infusion concentrations are commonly 4 g/ml with a
loading dose of 1 g/kg recommended over 10 minutes.
Infusion rates of 0.2-0.7 g/kg/hr can be continued for 24
hours. In the study, infusions were continued up to 30
days.
Antipsychotic Agents
Haloperidol is effective in the management of delirium
and has been recommended by the SCCM guidelines.1
Boluses of 1-5mg are useful in conjunction with other
sedative anxiolytics. Side effects can include QT
prolongation, hypotension and extrapyramidal
movement tics.
Neuromuscular Blocking Agents
Neuromuscular blocking agents are used sparingly in
today's ICU. Concerns include critical illness myopathy,
and awareness from inadequate sedation. Current
indications are reserved for patients with difficult
ventilation from high airway pressures, prevention of
shivering in patients undergoing hypothermia, and
malignant intracranial hypertension. Cisatracurium and
rocuronium are the commonly used non depolarizing
muscle relaxants, because of their relative
cardiostability. Cisatracurium undergoes hoffmans
degradation and similar to remifentanil is metabolized
by tissue and plasma esterases.
Sedations Use
Although new drugs continue to become available, it is
increasingly recognized that it is how sedatives are used
that requires a new approach.
Choices in Useage Include:
1. Continuous infusion
2. Bolus
3. Daily stop sedation trials
4. Sleep aids
5. Sedation protocols
6. Monitoring of sedation
VOL.11 NO.5 MAY 2006 Drug Review
33
L. 4 NO.9 SEPTEMBER 2009
A number of studies have shown the benefit of daily
stop of sedation trials over continuous infusions. Kress
et al. demonstrated a reduction in duration of
mechanical ventilation, length of ICU stay and fewer
investigations to look for cause of unexplained changes
of mental status.12,13
Most recently, the ABC trial randomized 335 ventilated
patients to a protocol that paired spontaneous
awakening trials (SATs)-ie, daily interruption of
sedatives-with spontaneous breathing trials (SBTs)
versus SBTs alone.14 Patients in the intervention group
spent more days breathing without assistance than the
control group (14.7 days vs 11.6 days; mean difference
3.1 days, 95% CI 0.7 to 5.6; p=0.02) and were discharged
from intensive care (median time 9.1 days vs 12.9 days;
p=0.01) and the hospital earlier (median time.9 days vs
19.2 days; p=0.04). More patients in the intervention
group self-extubated. (16 patients vs six patients; 6.0%
difference, 95% CI 0.6% to 11.8%; p=0.03), but the
reintubation rates were similar. Patients in the
intervention group were less likely to die than were
patients in the control group (HR 0.68, 95% CI 0.50 to
0.92; p=0.01). For every seven patients treated with the
intervention, one life was saved. (NNT 7.4, 95% CI 4.2 to
35.5) They concluded daily wake and breath trials
improve outcomes and should be employed
universally.
Nurse driven protocols have been validated and
involve nurse assessment of:5,6
Conclusions
Critically ill ventilated patients benefit from the
optimization of their sedation and analgesia
management. Sedation strategies must incorporate a
recognition and management of causes and precipitants
for pain and anxiety in ICU patients. Using sedation
scales can improve sedation titration and minimize over
and undersedation. Newer agents for sedation infusion
such as dexmedetomidine and remifentanil add to the
armament of the intensive care physician. The use of
daily sedation interruption together with daily
spontaneous wean protocols has been shown to
decrease mortality in the critically ill.
1. Sedation/Agitation Scale
2. Haemodynamic stability
3. Titration of sedation agent selected
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Table 1 Critical Care Pain Observational Tool
Indicator
Facial expression
Body movements
Muscle tension
Compliance with the
ventilator
OR Vocalisation
(extubated patients)
Scores for each of the four domains are summed, with a total score of 0 to 8 [34].
Sessler et al. Critical Care 2008 12(Suppl 3):S2
Score
Relaxed, neutral: 0
Tense: 1
Grimacing: 2
Absence of movements: 0
Protection: 1
Restlessness: 2
Relaxed: 0
Tense, rigid: 1
Very tense or rigid: 2
Tolerating ventilator or movement: 0
Coughing but tolerating: 1
Fighting ventilator: 2
Talking in normal tone or no sound: 0
Sighing, moaning: 1
Crying out, sobbing: 2
Descr iption
No muscular tension observed
Presence of frowning, brow lowering, orbit tightening, and levator contraction
All of the above facial movements plus eyelid tightly closed
Does not move at all (does not necessarily mean absence of pain)
Slow, cautious movements, touching or rubbing the pain site, seeking attention through
movements
Pulling tube, attempting to sit up, moving limbs/thrashing, not following commands,
striking at staff, trying to climb out of bed
No resistance to passive movements
Resistance to passive movements
Strong resistance to passive movements, inability to complete them
Alarms not activated, easy ventilation
Alarms stop spontaneously
Asynchrony: blocking ventilation, alarms frequently activated
Talking in normal tone or no sound
Sighing, moaning
Crying out, sobbing
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Table 2 Four Subjective Sedation Assessment Scales: A Comparison of Their Scoring
Agitated
Calm
Sedated
Source
Richmond Agitation Sedation
Scale (RASS)
+4 Combative
+3 Very agitated
+2 Agitated
+1 Restless
0 Alert and calm
-1 Drowsy
-2 Light sedation
-3 Moderate
-4 Deep sedation
-5 Unarousable
Sessler CN et al. AJRCCM 2002
;166(10) :1338-44
Ramsay Scale
1 Anxious, agitated, both
2 Cooperative, orientated & tranquil
3 Patient responds to command only
4 Brisk response to light glabella tap
5 sluggish response to light glabella tap
6 No response
Ramsay MA et al. BMJ 1974;2(5920):656-9
Motor Activity Assessment Scale
6 Dangerously agitated,
uncooperative
5 Agitated
4 Restless but cooperative
3 Calm and cooperative
2 Responsive to touch, name,
both
1 Responsive only to noxious
stimuli
0 Unresponsive
Devlin JW et al. CCM 1999
;27(7) :1271-5
Sedation Agitation Scale
7 Dangerously agitated
6 Very agitated
5 Agitated
4 Calm and cooperative
3 Sedated
2 Very Sedated
1 Unarousable
Riker R et al. CCM 1994 ;22(3)
:433-40
Table 3 A Comparison of Commonly Used ICU Sedative and Analgesic Agents
Drug
Midazolam
-Benzodiazepine
Propofol
Morphine
-Opioid
Remifentanil
-Opioid
Dexmedetomidine
Elimination
Cyt P450
Active metabolite
Conjugation
Conjugation
Active metabolite
Tissue Esterases
Cyt P450
Gluc?uronidation
Duration
1-4h
longer if elderly
liver/renal failure
3-10 mins
2-4hr
if long infusion
liver/renal failure
10-20 mins
6mins
in liver failure
Dosing IV
LD 2-5mg
MD 1-10mg/hr
MD 5-150
g/kg/min
LD 2-4mg
MD 1-20mg/hr
LD 1 g/kg- 1min
MD 0.6-1.5
g/kg/hr
LD 1 g/kg-10mn
MD 0.2-0.7
g/kg/hr for 24hr
Concentration
1mg/ml
10mg/ml
Undiluted
1mg/ml
20, 25, 50 g/ml
2 g/ml
Advantages
Short acting
Cardiac stable
Short Acting
Rapid offset
ICP
wean time
Anxiolytic
HR, RR
Cheap
No accumulation rapid
offset
wean time
Rapid offset
No respiratory depression
Withdrawal Mx
wean time
delirium
Disadvantages
Delirium
Dependance
Withdrawal
Propofol infusion
syndrome
BP, lipid,
amylase
Resp depression,
BP, withdrawal,
GI absorbtion
HR, BP, ICP
acute withdrawal
HR, BP,
Not > 24hrs
expensive
Relative Cost
$$$
$$$$
$
$$$
$$$$$
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When I was five years old and living in California, I
nearly drowned in a neighbour's swimming pool. I still
remember the frantic struggle to keep my head above
water, my heart pounding so hard that I thought my
chest would burst and the overwhelming fear and panic
until I was pulled to safety. Perhaps because of this
personal history, I made sure my two daughters learned
to be good swimmers and to love the water. We enjoyed
many beach holidays while they were growing up, but
as they became more competent and adventurous
swimmers, I was more likely to be found close to the
shore (wearing a life vest for security) or covered with
sunblock and reading at the poolside.
On one such holiday, my elder daughter took a resort
scuba diving course with her father. My younger
daughter was too young to participate so she and I
snorkelled. From the surface we could see the two of
them amongst all the beautiful fish and coral. The sun
warmed our backs as we floated mesmerised by the
view. It was like looking down into a giant aquarium.
My elder daughter was so enthused by her first scuba
experience that when we returned to Hong Kong she
and her father immediately enrolled in a course to
become PADI certified divers. When my younger
daughter reached eligible age, it was clear that she
would have to take the course alone unless I agreed to
take it with her. Truthfully, given my childhood
trauma, I was not at all keen and was in fact more than
a little scared. However, my love and empathy for my
little daughter was greater than the sum of all my fears.
Besides, I did not want to be left completely behind, so
the two of us signed up.
Despite my determination, the prospect of diving was
stressful. I dealt with this in the same manner that most
doctors face difficult circumstances: hope for the best,
but prepare for the worst. My 11 year-old and I studied
the course material together in the evenings after she
finished her regular schoolwork and on weekends.
Actually, it was fun reviewing and explaining basic gas
laws, concepts of balance and buoyancy, and
rudimentary lung and exercise physiology. I insisted
that we also study water safety rules, underwater
dangers (such as currents, venomous plants and
animals, sharks, etc.) and common water-related
injuries and illnesses. We both passed the written
examinations without difficulty and moved onto the
practical skills. Completely comfortable around water,
my daughter had no trouble passing the closed water
exam which was conducted in a swimming pool. For
me, though, just putting on the wetsuit, which fit rather
too snugly on my not-so-buffed middle-aged body, was
a huge struggle, and I found that the mask (I don't
know how people can sleep with a CPAP mask) seemed
to heighten the sense of tension and anxiety.
Furthermore, descending underwater to scuba requires
the diver to wear weights, to actively deflate a flotation
device and not to kick one's finned legs to propel
upward. These steps to "let go" of the surface are
counter-intuitive for someone who had nearly drowned
- even more so than might be expected for a person who
by nature is rather cautious and has been accused by
her children as being somewhat obsessive and
controlling. While I really wanted to be able to dive
with my little daughter and though intellectually I
knew that I was prepared and perfectly "safe," I felt all
my childhood fears and anxiety about drowning
resurface during the closed water dive. It was really
terrible.
Our teacher was incredibly patient and kind. His day-
job was as an investment banker, yet he seemed to
understand my difficulties. He knew that I was far
beyond my comfort zone. He suggested that I just think
things through and take my time. Convinced that
diving was something that I really wanted to do and
would enjoy, he volunteered to spend extra sessions
with me to practise all the skills and help me feel more
confident. I am forever grateful for his gentle
encouragement and forbearance. Without his generosity
and support, I might have given up at this stage. By the
time we were scheduled to take the open water test in
Australia, I felt I was ready.
We had been to the resort where we scheduled the open
water examination before and I knew that the safety
standards were very high. A dive boat took us out near
Cod Hole in the Great Barrier Reef. It was a glorious,
cloudless day. As we waited for our divemaster's
instruction to descend, we bobbed at the ocean surface,
suspended at the interface between infinite skies and
the seemingly endless deep below. We were just three
little specks in a vast blue universe.
The divemaster signalled us to descend. The gentle
rocking of the surface waves was soon echoed by the
sounds of our own breathing. The rhythm and pace of
our respiration were somehow reassuring, an
affirmation that we were fine. Below the surface, the
waters were teeming with life. The colourful, some
almost highlighter-fluorescent-hued, tropical fish were
like confetti in the sunlight streaming from above. The
plant life was similarly vibrant. The coral gardens were
spectacular. It was all so beautiful and now my
daughter and I were not just looking at, but were part
Scuba Diving
Dr. Gloria PEI
Dr. Gloria PEI
Consultant in Internal Medicine, Hong Kong Adventist Hospital
MD(UCLA, USA), DABIM, HKCP, FHKAM
Life Style
36
VOL.14 NO.9 SEPTEMBER 2009
of, this fantastic aquarium. When we resurfaced at the
end of our dive, my little daughter read my mind when
she exclaimed, "Wow, that was great!"
My daughter and I successfully completed the exam
and were PADI certified on her twelfth birthday.
Luckily for us, there are many wonderful dive
destinations in the region, and we try to take a dive trip
every year. Our experiences have been amazing. One
year, we woke up before 5 am so that we could see the
humphead wrasses feed. As dawn broke, they came,
maybe 50 of them, like a majestic herd of bison or a
regiment of soldiers all marching in one direction.
Then, suddenly, in a flash, they all turned and swam
away in the direction from which they came. (This sight
was so impressive, that my daughters insisted that we
do it again the next morning! It was just as startling the
second time.) On one occasion, my daughters and I
hovered in the vortex of circling jack fish, the silver
bodies swirling and enclosing us in a little piscean
tornado. One of my favourite photographs of my
younger daughter is of her swimming alongside a
Napolean fish as big as she was. The fish was big and
friendly, like the family dog, leaning into us and
allowing us to pet its body. It swam beside her until it
was time for us to return to the dive boat and then
continued alongside the boat for a while. On another
trip, we came across a group of 15 sea turtles resting
near some barrel sponges. It was like a scene out of
"Finding Nemo." As we passed near them, they began
to swim. I found myself looking eye to eye with one
large turtle, which perhaps had been swimming in the
waters as long as I had been alive. Its eyes were clear
and shiny. We have seen many sharks over the years.
The sight of their natural grace and beauty do not fill
one fear, but rather deep awe.
These are just some of the memories I will cherish
forever and which draw me back to the waters. I
decided to learn to scuba dive for the sake of my
daughters, but I have benefitted far more than they
have from the experience. Becoming a PADI-certified
diver has been a transforming, instructive and
rewarding process, and scuba diving is an activity that I
now truly enjoy. In addition to being able to continue
an activity with my now grown daughters, through
diving, I have learned to appreciate that we are never
too old to face a challenge, to overcome fears, or to learn
new skills with which we can continue to explore our
beautiful world.
Dermatological Quiz
Dermatological Quiz
Dr. Lai-yin CHONG
Dr. Lai-yin CHONG
(See P. 41 for answers)
A 50-year-old man developed these asymptomatic patches at his
abdominal walls for six months. The lesions gradually increased in size.
There were no systemic symptoms. He was otherwise well in health. On
palpation, these lesions were indurated and confined to the abdominal
wall. Skin scraping for fungi was negative.
1. What is your provisional diagnosis and differential diagnoses?
2. What investigations will you perform?
3. What are the treatment options available?
4. What is the prognosis of this disease?
Multiple circumscribed sclerotic
patches with active border at the
abdomen
Questions:
Yaumatei Dermatology Clinic, Social Hygiene Service
MBBS(HK), FRCP(Lond, Edin, Glasg), FHKCP, FHKAM(Med)
VOL.11 NO.5 MAY 2006 Medical Diary of September
37
L. 4 NO.9 SEPTEMBER 2009
Su
nd
ay
M
on
da
y
Tu
es
da
y
W
ed
ne
sd
ay
T
hu
rs
da
y
Fr
id
ay
Sa
tu
rd
ay
17
18
19
20
21
22
28
27
29
30
13
14
15
16
10
11
12
9
6
7
23
8
3
4
2
1
5
24
25
26
H
K
M
A
-T
ai
Po
C
om
m
un
ity
N
et
w
or
k
C
M
E
Le
ct
ur
e:
M
an
ag
em
en
to
fS
ki
n
A
lle
rg
ie
s
C
er
tif
ic
at
e
C
ou
rs
e
on
C
lin
ic
al
O
ph
th
al
m
ol
og
y
C
er
tif
ic
at
e
C
ou
rs
e
on
C
lin
ic
al
O
ph
th
al
m
ol
og
y
C
er
tif
ic
at
e
C
ou
rs
e
on
C
lin
ic
al
O
ph
th
al
m
ol
og
y
C
er
tif
ic
at
e
C
ou
rs
e
on
C
lin
ic
al
O
ph
th
al
m
ol
og
y
C
er
tif
ic
at
e
C
ou
rs
e
on
C
lin
ic
al
O
ph
th
al
m
ol
og
y
Rh
in
iti
s,
Si
nu
si
tis
an
d
N
as
al
Po
ly
po
si
s
-
Pr
ac
tic
al
Su
gg
es
tio
ns
fo
rG
en
er
al
Pr
ac
tit
io
ne
rs
H
K
M
A
C
ou
nc
il
M
ee
tin
g
Jo
in
tS
ur
gi
ca
lS
ym
po
si
um
-L
at
es
tA
ch
ie
ve
m
en
ts
an
d
D
ev
el
op
m
en
ts
H
K
M
A
Tr
ai
lw
al
ke
r
Tr
ai
ni
ng
Se
ss
io
n
4
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
H
K
M
A
Ba
dm
in
to
n
To
ur
na
m
en
t
H
K
M
A
Ba
dm
in
to
n
To
ur
na
m
en
t
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
H
K
M
A
Te
nn
is
To
ur
na
m
en
t
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
Re
co
un
tin
g
th
e
Ex
pe
ri
en
ce
an
d
Im
pa
ct
of
H
on
g
K
on
g
St
ud
en
ts
W
ho
St
ud
ie
d
M
ed
ic
in
e
in
W
ar
-ti
m
e
C
hi
na
H
K
M
A
St
ru
ct
ur
ed
C
M
E
Pr
og
ra
m
m
e
w
ith
PM
H
Ye
ar
20
09
(8
)-
i)
U
se
of
D
ru
gs
in
O
ld
A
ge
ii)
H
yp
er
te
ns
io
n
on
O
ld
A
ge
H
K
M
A
Tr
ai
lw
al
ke
r
Tr
ai
ni
ng
Se
ss
io
n
5
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
C
er
tif
ic
at
e
C
ou
rs
e
on
Re
sp
ir
at
or
y
M
ed
ic
in
e
20
09
C
er
tif
ic
at
e
C
ou
rs
e
on
Re
sp
ir
at
or
y
M
ed
ic
in
e
20
09
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
H
K
N
eu
ro
su
rg
ic
al
So
ci
et
y
M
on
th
ly
A
ca
de
m
ic
M
ee
tin
g
-
C
av
er
no
m
a
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
Th
e
C
os
m
et
ic
A
ca
de
m
ic
Ex
ch
an
ge
W
or
ks
ho
p
fo
rB
TX
A
(B
ot
ul
in
um
To
xi
n
Ty
pe
A
)
H
K
M
A
St
ru
ct
ur
ed
C
M
E
Pr
og
ra
m
m
e
w
ith
H
on
g
K
on
g
Sa
na
to
ri
um
&
H
os
pi
ta
lY
ea
r
20
09
-N
ew
Tr
en
ds
in
M
an
ag
em
en
to
f
V
itr
eo
-R
et
in
al
-
M
ac
ul
ar
D
is
ea
se
s
-
Fr
om
D
ia
gn
os
is
to
Tr
ea
tm
en
t
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
t
W
or
ks
ho
p
H
K
M
A
C
M
E
-G
lit
az
on
e
fo
r
Ty
pe
2
D
M
M
an
ag
em
en
t-
In
si
gh
ts
fr
om
Re
ce
nt
O
ut
co
m
e
Tr
ia
ls
H
K
M
A
-S
ha
tin
D
oc
to
rs
N
et
w
or
k
-C
er
tif
ic
at
e
C
ou
rs
e
on
O
st
er
op
or
os
is
(1
)B
ub
bl
es
,B
ub
bl
es
,
Bu
bb
le
s
(2
)T
B
or
no
tT
B
H
K
M
A
G
ol
fT
ou
rn
am
en
t
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
FM
SH
K
Ex
ec
ut
iv
e
C
om
m
itt
ee
M
ee
tin
g
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
H
K
M
A
/M
PS
Ri
sk
M
an
ag
em
en
tW
or
ks
ho
p
C
er
tif
ic
at
e
C
ou
rs
e
on
C
lin
ic
al
Et
hi
cs
in
Pr
ac
tic
e
C
er
tif
ic
at
e
C
ou
rs
e
on
C
lin
ic
al
Et
hi
cs
in
Pr
ac
tic
e
C
er
tif
ic
at
e
C
ou
rs
e
on
C
lin
ic
al
Et
hi
cs
in
Pr
ac
tic
e
H
K
M
A
C
er
tif
ic
at
e
C
ou
rs
e
on
Fa
m
ily
M
ed
ic
in
e
20
09
M
an
ag
em
en
to
fD
ru
g
A
bu
se
rs
on
Pu
bl
ic
-P
ri
va
te
In
te
rf
ac
e
-S
es
si
on
O
ne
M
an
ag
em
en
to
fD
ru
g
A
bu
se
rs
on
Pu
bl
ic
-P
ri
va
te
In
te
rf
ac
e
-S
es
si
on
O
ne
C
er
tif
ic
at
e
C
ou
rs
e
on
D
en
ta
lN
ur
si
ng
in
O
ra
l
Su
rg
er
y
C
er
tif
ic
at
e
C
ou
rs
e
on
D
en
ta
lN
ur
si
ng
in
O
ra
l
Su
rg
er
y
C
er
tif
ic
at
e
C
ou
rs
e
on
D
en
ta
lN
ur
si
ng
in
O
ra
l
Su
rg
er
y
C
er
tif
ic
at
e
C
ou
rs
e
on
D
en
ta
lN
ur
si
ng
in
O
ra
l
Su
rg
er
y
FM
SH
K
O
ffi
ce
rs
'M
ee
tin
g
Medical Diary of September
38
VOL.14 NO.9 SEPTEMBER 2009
Ms. Paulina TANG
Tel: 2527 8898 Fax: 2865 0345
8:00 pm - 10:00 pm17 THU
FMSHK Executive Committee Meeting
Organised by: The Federation of Medical Societies of Hong Kong, Venue: Council
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Bioethics Association, Speakers: Various, Venue: Lecture Hall, 4/F, Duke of Windsor
Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
Ms. Dora HO
Tel: 2527 828516 WED HKMA Golf TournamentOrganised by: The Hong Kong Medical Association, Venue: Hong Kong Golf Club
2:00 pm Miss Alice TANG /
Mr. Kevin CHAN
Tel: 2527 8285 / 2595 694114 MON
Management of Drug Abusers on Public-Private Interface - Session One
Organised by: HKMA -Tin Shui Wai, Tuen Mun and Yuen Long Community Networks
and New Territories West Cluster Anti-Drug Abuse Committee of Tuen Mun Hospital,
Chairman: Dr. LEE Fook Kay Aaron, Speakers: Various, Venue: Lecture Theatre, 2/F,
Ambulatory Care Center, Tuen Mun Hospital, 23 Tsing Chung Koon Road, New
Territories
Miss Viviane LAM
Tel: 2527 8452
1 CME Point
HKMA CME - Glitazone for Type 2 DM Management - Insights from Recent Outcome Trials
Organised by: The Hong Kong Medical Association, Speaker: Dr. CHAN Wing Bun,
Venue: Mongkok
Miss Alice TANG
Tel: 2527 8285
Rhinitis, Sinusitis and Nasal Polyposis - Practical Suggestions for General Practitioners
Organised by: HKMA - Central, Western & Southern Community Network, Chairman:
Dr. CHAN Hau Ngai Kingsley, Speaker: Dr. Paul LAM, Venue: The HKMA Dr. Li Shu
Pui Professional Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road
Central, Hong Kong
Miss Viviane LAM
Tel: 2527 8452
2 CME Points
HKMA/MPS Risk Management Workshop
Organised by: The Hong Kong Medical Association, Speaker: Dr. Anne KOLBE & Dr. Jo
BURNAND, Venue: The HKMA Dr. Li Shu Pui Professional Education Centre, 2/F,
Chinese Club Building, 21-22 Connaught Road Central, Hong Kong
Department of Surgery, Hong
Kong Sanatorium & Hospital
Tel: 2835 8698 Fax: 2892 7511
1 CME Point (Active)
8:00 am - 9:00 am4 FRI
Joint Surgical Symposium - Latest Achievements and Developments
Organised by: Department of Surgery, The University of Hong Kong & Hong Kong
Sanatorium & Hospital, Chairman: Prof. William WEI, Speakers: Dr. CHAN Yu-Wai &
Dr. Vivian MOK, Venue: Hong Kong Sanatorium & Hospital
Ms. Dora HO
Tel: 2527 8285
2:00 pm6 SUN
HKMA Badminton Tournament
Organised by: The Hong Kong Medical Association, Venue: MacLehose Medical
Rehabilitation Centre
Ms. Erica HUNG
Tel: 2527 8898 Fax: 2865 0345
Website: http://www.fmshk.org
9 CNE Points /
CME/CPD Accreditation in
Application
7:00 pm - 8:30 pm Certificate Course on Dental Nursing in Oral Surgery
Organised by: The Federation of Medical Societies of Hong Kong & The Hong Kong
Association of Oral and Maxillofacial Surgeons Limited, Speakers: Various, Venue:
Lecture Hall, 4/F, Duke of Windsor Social Service Building, 15 Hennessy Road,
Wanchai, Hong Kong
Ms. Erica HUNG
Tel: 2527 8898 Fax: 2865 0345
Website: http://www.fmshk.org
9 CNE Points /
CME/CPD Accreditation in
Application
7:00 - 8:30 pm2
WED
Certificate Course on Clinical Ophthalmology
Organised by: The Federation of Medical Societies of Hong Kong & The Hong Kong
Ophthalmological Society, Speakers: Various, Venue: Lecture Hall, 4/F, Duke of
Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
Miss Alice TANG
Tel: 2527 8285
1.5 CME Points
1:00 pm
8:00 pm - 10:00pm
1 TUE
HKMA - Tai Po Community Network CME Lecture: Management of Skin Allergies
Organised by: HKMA - Tai Po Community Network, Speaker: Dr. HO Hok Kung
Marco, Venue: Tai Po
Ms. Paulina TANG
Tel: 2527 8898 Fax: 2865 0345
FMSHK Officers' Meeting
Organised by: The Federation of Medical Societies of Hong Kong, Venue: Gallop, 2/F.,
Hong Kong Jockey Club Club House, Shan Kwong Road, Happy Valley, Hong Kong
Date / Time Function Enquiry / Remarks
(20)
(19,26)
(21)
Mr. Sean WONG / Mr. P.C. YU
Tel: 2771 6622
12:00 pm - 3:00 pm10 THU
The Cosmetic Academic Exchange Workshop for BTXA (Botulinum Toxin Type A)
Organised by: Hugh Source (International) Ltd, Venue: The Mira Hong Kong Hotel
(TST), Registration: Limited seat, please book in advance (Free admission)
Miss Viviane LAM
Tel: 2527 8452
1 CME Point
2:00 pm HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital Year
2009 - New Trends in Management of Vitreo-Retinal-Macular Diseases - From
Diagnosis to Treatment
Organised by: The Hong Kong Medical Association, Speaker: Dr. CHAN Wai Man,
Venue: The HKMA Dr. Li Shu Pui Professional Education Centre, 2/F, Chinese Club
Building, 21-22 Connaught Road Central, Hong Kong
(6,7,8,9,10,11,12,15,
16,17,19,20,21,22)
(11,18,25)
(9,16,23,30)
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Ms. Erica HUNG
Tel: 2527 8898 Fax: 2865 0345
Website: http://www.fmshk.org
9 CNE Points /
CME/CPD Accreditation in
Application
7:00 pm - 8:30 pm22 TUE
Certificate Course on Respiratory Medicine 2009
Organised by: The Federation of Medical Societies of Hong Kong; Hong Kong Thoracic
Society & American College of Chest Physicians (HK & Macau Chapter), Speakers:
Various, Venue: Lecture Hall, 4/F, Duke of Windsor Social Service Building, 15
Hennessy Road, Wanchai, Hong Kong
Ms. Dora HO
Tel: 2527 8285
7:30 pm19 SAT HKMA Trailwalker Training Session 5Organised by: The Hong Kong Medical Association, Venue: MacLehose Stage 4-6
Meetings
Annual Scientific Meeting in Anaesthesiology 2009
Organised by: The Hong Kong College of Anaesthesiologists & The Society of Anaesthetists of Hong Kong, Chairman: Dr. S.T.
TAN, Venue: The Hong Kong Academy of Medicine Building, Enquiry: ASM 2009 Secretariat, Tel: 2559 9973, Fax: 2547 9528,
Email: asm2009@icc.com.hk, Website: http://www.anaesthesiology.hk
3rd Joint Scientific Meeting of The Royal College of Radiologists and Hong Kong College of Radiologists and 17th Annual
Scientific Meeting of Hong Kong College of Radiologists
Organised by: The Royal College of Radiologists & Hong Kong College of Radiologists, Venue: Hong Kong Academy of
Medicine, Jockey Club Building, 99 Wong Chuk Hang Road, Aberdeen, Hong Kong, Enquiry: Secretariat, Tel: 2871 8788, Fax:
2554 0739, Email: enquiries@hkcr.org, Website: http://www.hkcr.org
OSHK A-Z Symposia Series "B" - Symposium: "B" Isphosphonate-Related Osteonecrosis of the Jaw and the New OSHK
Guidelines on Osteoporosis Management
Organised by: The Osteoporosis Society of Hong Kong, Venue: Shanghai Room, Level 8, Langham Place Hotel, Mongkok,
Kowloon, Enquiry: Secretariat, Tel: 2881 4295, Fax: 2159 7242
International Symposium on Hepatology 2009 / 22nd Annual Scientific Meeting
Organised by: The Hong Kong Association for the Study of Liver Diseases, Venue: Hong Kong Convention and Exhibition
Centre, Enquiry: Ms. Melissa LEUNG, CMPMedica Pacific Limited, Tel: 2116 4348, E-mail: melissa.leung@asia.cmpmedica.com
Hong Kong Surgical Forum - Winter 2010
Organised by: Department of Surgery, the University of Hong Kong, Queen Mary Hospital & Hong Kong Chapter of American
College of Surgeons, Venue: Undeground Lecture Theatre, New Clinical Building, Queen Mary Hospital, Pokfulam, Hong
Kong, Enquiry: Forum Secretariat, Tel: 2855 4855 / 2855 4886, Fax: 2819 3416, Email: hksf@hkucc.hku.hk, Website:
http://www3.hku.hk/surgery/forum/php
23-25/10/2009
31/10/2009 -
1/11/2009
1/11/2009
8/11/2009
9/1/2010
Courses
Advanced Trauma Life Support (ATLS) Student Course
Organised by: Department of Surgery, Queen Mary Hospital & Hong Kong Chapter of the American College of Surgeons,
Venue: The Jockey Club Skills Development Centre, C3, Main Block, Queen Mary Hospital, Pokfulam, Hong Kong, Enquiry:
Course Administrator, Tel: 2855 4885 / 2855 4886, Fax: 2819 3416, Email: hnsrg@hkucc.hku.hk, Web site:
http://www.hku.hk/surgery
Advanced Trauma Care for Nurses (ATCN) Provider Course
Organised by: Department of Surgery, Queen Mary Hospital & Hong Kong Chapter of the American College of Surgeons # The
Jockey Club Skills Development Centre, C3, Main Block, Queen Mary Hospital, Pokfulam, Hong Kong Enquiry: Course
Administrator Tel: 2855 4885 / 2855 4886 Fax: 2819 3416 Email: hnsrg@hkucc.hku.hk Web site: http://www.hku.hk/surgery
PALS Paediatric Advanced Life Support Course 2009
Organised by: Hong Kong College of Paediatricians, the Heart Institute for Children, Hope Children's Hospital, Illinois, USA
& Hong Kong Paediatric Nurses Association, Speakers: Various, Venue: A & E Training Centre, Tang Shiu Kin Hospital,
CME Accreditation: 12 Points for Provider Course, Enquiry: Ms. Vanessa WONG, Tel: 2871 8773, Fax: 2785 1850, Email:
enquiry@paediatrician.org.hk, Website: http://www.paediatrician.org.hk/entcnews.htm (Application starting now until
August 09)
Advanced Medical Life Support (AMLS) Provider Course
Organised by: Department of Surgery, Queen Mary Hospital & Hong Kong Chapter of the American College of Surgeons,
Venue: The Jockey Club Skills Development Centre, C3, Main Block, Queen Mary Hospital, Pokfulam, Hong Kong, Enquiry:
Course Administrator,
Tel: 2855 4885 / 2855 4886, Fax: 2819 3416, Email: hnsrg@hkucc.hku.hk Web site: http://www.hku.hk/surgery
20-22/11/2009
20-21/11/2009
3-7/10/2009
12-13/12/2009
Dr. James C.M. HO / Dr. Johnny
W.M. CHAN
Tel: 2855 4999 Fax: 2872 5828
1 CME Point
6:30 pm - 8:00 pm24 THU
(1) Bubbles, Bubbles, Bubbles (2) TB or not TB
Organised by: Hong Kong Thoracic Society / ACCP(HK & Macau Chapter),
Chairpersons: Dr. YU Wai Cho & Dr. WONG Mo Lin Maureen, Speakers: Dr. Jones
KWOK, Dr. YEUNG Yiu Cheong & Dr. YAU Pak Yuen, Venue: LG1, Lecture Room,
Ruttonjee Hospital, Hong Kong
Ms. Cathy HUNG / Mr. Ringo NG
Tel: 2549 5123
4:00 pm - 6:00 pm26 SAT
Recounting the Experience and Impact of Hong Kong Students Who Studied Medicine
in War-time China
Organised by: Hong Kong Museum of Medical Sciences Society, Chairman: Dr. LEE
Kin Hung, Speakers: Dr. Joseph PAN, Dr. CHUA Sin Giap & Dr. Ramon RUIZ, Venue:
Auditorium, 4/F, Li Shu Pui Block, Hong Kong Sanatorium & Hospital, Hong Kong
Miss Viviane LAM
Tel: 2527 8452
CME Points
2:00 pm
7:30 pm
27 SUN
HKMA Structured CME Programme with PMH Year 2009 (8) - i) Use of Drugs in Old
Age ii) Hypertension on Old Age
Organised by: The Hong Kong Medical Association, Speakers: Dr. KONG Tak Kwan &
Dr. AU Kai Man, Venue: G8 Hall, Princess Margaret Hospital
Ms. Dora HO
Tel: 2527 8285
HKMA Tennis Tournament
Organised by: The Hong Kong Medical Association, Venue: Kowloon Tong Club
Miss Alice TANG
Tel: 2527 8285
1.5 CME Points
2:00 pm23 WED
HKMA-Shatin Doctors Network - Certificate Course on Osteroporosis
Organised by: HKMA-Shatin Doctors Network, Chairman: Dr. Ben FONG, Speakers:
Ms. Jamie LAU & Ms. Barbara CHAN, Venue: Shatin
Date / Time Function Enquiry / Remarks
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The Federation President Cup Soccer Five Tournament 2009 was held in Macau on the 12 
July 2009. Prior to the tournament, Dr. Kingsley Chan delivered a session sharing on the 
"Update Treatment on Acne" on 11 July 2009 evening, which was sponsored by Stiefel 
Laboratories. 45 participants attended the dinner, with 17 practising doctors in Macau.
The Soccer Five Tournament was held on Sunday, 12 July 2009.  There were eight 
participating teams, six from Hong Kong and two from Macau.  They were:
The tournament started as early as 8.30am.  After rounds 
of 16 matches, it finished at 5.40pm.  Congratulations to 
the winning teams: 
The two Top Scorers go to Mr. Nicholas Chan of the 
Pfizer Corporation (HK) Ltd team and Mr. Alex Lam of 
the Federation Inviting Team.
The event ended with a cocktail party and award 
presentation ceremony.
Alcon (Hong Kong) Limited (HK)
AstraZeneca Hong Kong Limited (HK)
Centro Hospitalar Conde de Sao Januario, CHCSJ (Macau)
Federation Inviting Team (HK)
Hong Kong Ophthalmological Society (HK)
Hong Kong Medical Association (HK)
Kiang Wu Hospital (Macau)
Pfizer Corporation (HK) Ltd (HK)
Champion - Pfizer Corporation (HK) Ltd 
1st Runner up - Federation Inviting Team 
2nd Runner up - AstraZeneca Hong Kong Limited
The Federation President Cup Soccer Five Tournament 2009 
Invited guests officiating at the opening ceremony
From left to right: Dr. Jimmy Lai (Committee), Ms. Tina Yap (Committee), 
Dr. Susanna Lo (2nd Vice President), Dr. Raymond Lo (1st Vice 
President), Dr. Dawson Fong (President), Dr. Lee Pui I  (President of 
Macau Physician Association of Public Hospital), Dr. Tse Hung-hing 
(President of HKMA), Dr. Liu Wing-hong (Co-chairmen), Mr. Nelson Lam 
(Co-chairmen), Dr. Kingsley Chan (Co-chairmen) 1st Runner up - Federation Inviting Team 
2nd Runner up - AstraZeneca Hong Kong Limited
Top Scorers 
From left to right: 
Mr. Nicholas Chan (Pfizer Corporation (HK) Ltd), 
Dr. Liu Wing-hong (Co-chairmen), 
Mr. Alex Lam (Federation Inviting Team) 
The Champion - Pfizer Corporation (HK) Ltd
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Dr. Lai-yin CHONG
Yaumatei Dermatology Clinic, Social Hygiene Service
MBBS(HK), FRCP(Lond, Edin, Glasg), FHKCP, FHKAM(Med)
Patron
The Honourable
Donald TSANG, GBM ?????
President
Dr. FONG To-sang, Dawson ?????
1st Vice-President
Dr. LO See-kit, Raymond ?????
2nd Vice-President
Dr. LO Sze-ching, Susanna ?????
Hon. Treasurer
Mr. LAM Lop-chi, Nelson ?????
Deputy Hon. Treasurer
Mr. LEE Cheung-mei, Benjamin ?????
Hon. Secretary
Dr. CHAN Sai-kwing ?????
Executive Committee Members
Dr. CHAN Chi-fung, Godfrey ?????
Dr. CHAN Chi-kuen ?????
Dr. CHAN Hau-ngai, Kingsley ?????
Dr. CHIM Chor-sang, James ?????
Dr. CHOI Kin ????
Ms. KU Wai-yin, Ellen ?????
Dr. LEE Kin-man, Philip ?????
Dr. MAN Chi-wai ?????
Dr. MOK Chun-on ?????
Dr. MUI, Winnie ??????
Dr. NG Yin-kwok ?????
Dr. YU Chau-leung, Edwin ?????
Dr. YU Kong-san ?????
The Federation of Medical Societies of Hong Kong
4/F Duke of Windsor Social Service Building,
15 Hennessy Road, Wanchai, Hong Kong
Tel: 2527 8898 Fax: 2865 0345
President
Dr. TSE Hung-hing ?????
Vice- Presidents
Dr. CHAN Yee-shing, Alvin ?????
Dr. CHOW Pak-chin ?????
Hon. Secretary
Dr. LO Chi-fung, Ernie ?????
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Dr. LEUNG Chi-chiu ?????
Council Representatives
Dr. CHAN Yee-shing ?????
Dr. CHOI Kin ????
Chief Executive
Mrs. LEUNG, Yvonne ??????
Tel: 2527 8285 (General Office)
2527 8324 / 2536 9388 (Club House in Wanchai / Central)
Fax: 2865 0943 (Wanchai), 2536 9398 (Central)
Email: hkma@hkma.org
Website: http://www.hkma.org
President
Dr. WU, Adrian ?????
Vice-President
Dr. LO See-kit, Raymond ?????
Hon. Secretary
Dr. LI, Anthony ?????
Hon. Treasurer
Dr. LEUNG, Clarence ?????
Council Representatives
Dr. LO See-kit, Raymond ?????
Dr. CHEUNG Tse-ming ?????
Tel: 2527 8898 Fax: 2865 0345
Board of Directors
President
Dr. FONG To-sang, Dawson ?????
1st Vice-President
Dr. LO See-kit, Raymond ?????
2nd Vice-President
Dr. LO Sze-ching, Susanna ?????
Hon. Treasurer
Mr. LAM Lop-chi, Nelson ?????
Hon. Secretary
Dr. CHAN Sai-kwing ?????
Directors
Dr. CHAN Chi-kuen ?????
Mr. CHAN Yan-chi, Samuel ?????
Dr. CHIM Chor-sang, James ?????
Mr. LEE Cheung-mei, Benjamin ?????
Dr. WONG Mo-lin, Maureen ?????
Founder Members
Answer to Dermatological Quiz
1. Morphoea (localized scleroderma)
The differential diagnoses in this patient included mycosis
fungoides, tinea corporis and erythema annulare
centrifugum. Morphoea is an inflammatory disease
primarily affects dermis and subcutaneous fat of skin,
resulting in sclerosis and deformity. It is a distinct entity
with a clinical course completely different from systemic
scleroderma, though histologically the two conditions are
identical in the skin lesions. Morphoea occasionally can be
generalized and simulate diffuse scleroderma, but systemic
involvements are absent. Raymond's phenomenon is also
absent in morphoea but present in 90% of systemic
scleroderma.
Skin biopsy for histopathology should be done to confirm
the diagnosis.
Various topical medications have been used but the results
are unsatisfactory in general. These include topical or
intralesional corticosteroids, topical calcineurin inhibitors,
topical vitamin A and vitamin D analogues. For
generalized morphoea, UVA1 or bath PUVA phototherapy
seems promising. For rapidly progressive disabling
disease, weekly methotrexate combined with pulsed
therapy of corticosteroids has recently been advocated by
some workers.
With the absence of systemic involvement, morphoea is not
fatal as in its systemic counterpart. However, it does cause
significant morbidity with the resulted disfigurement, or
functional disabilities due to contractures. In severe lesions,
the underlying muscle and bone may be involved. The
disease often progresses for several years before finally
regresses and burns out.
1.
2.
3.
4.

